路径ID,路径描述,间接效应均值,间接效应HDI下限,间接效应HDI上限,间接效应标准差,直接效应均值,直接效应HDI下限,直接效应HDI上限,直接效应标准差,总效应均值,总效应HDI下限,总效应HDI上限,总效应标准差,中介比例,中介比例百分比,主要影响类型,影响强度,间接效应方向,直接效应方向,中介类型,显著性概率,是否显著,正向效应概率,负向效应概率,结论
1,检验_中性粒细胞比率 → 检验_中性粒细胞数量 → 检验_白细胞,0.2606,0.1898,0.3321,0.0384,-0.0177,-0.1241,0.0845,0.0555,0.2429,0.1355,0.3431,0.0554,1.1251,112.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为112.5%。
2,检验_中性粒细胞比率 → 检验_中性粒细胞数量 → 检验_单核细胞数量,0.1461,0.0789,0.2096,0.0345,0.0646,-0.056,0.1823,0.0636,0.2108,0.1058,0.3178,0.0562,0.755,75.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为75.5%。
3,检验_中性粒细胞比率 → 检验_中性粒细胞数量 → 检验_镁,0.0675,0.0067,0.1332,0.0337,0.0284,-0.1026,0.1473,0.0662,0.0959,-0.013,0.2011,0.0571,1.0094,100.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.9785,是,0.9785,0.0215,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为100.9%。
4,检验_中性粒细胞比率 → 检验_中性粒细胞数量 → 药物_复方鲜竹沥液,0.0274,-0.035,0.0912,0.0337,0.0448,-0.079,0.1743,0.069,0.0722,-0.0419,0.1824,0.0595,0.2976,29.8,直接影响,强,正向中介,正向直接效应,部分中介,0.7905,否,0.7905,0.2095,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为29.8%。
5,检验_中性粒细胞比率 → 检验_中性粒细胞数量 → 药物_苯磺酸氨氯地平片,-0.0572,-0.1233,0.0012,0.0334,-0.0284,-0.1444,0.0979,0.0654,-0.0856,-0.1961,0.018,0.0565,0.823,82.3,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.958,是,0.042,0.958,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为82.3%。
6,检验_中性粒细胞比率 → 检验_淋巴细胞比率 → 检验_淋巴细胞数量,0.2784,0.181,0.3728,0.0511,0.0285,-0.1068,0.1559,0.0709,0.307,0.2011,0.4062,0.0553,0.936,93.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为93.6%。
7,检验_中性粒细胞比率 → 检验_淋巴细胞比率 → 药物_维生素B6注射液,0.0705,-0.0381,0.1588,0.0528,0.0709,-0.0841,0.2143,0.0783,0.1415,0.0367,0.2571,0.0591,0.8428,84.3,直接影响,强,正向中介,正向直接效应,完全中介,0.9105,否,0.9105,0.0895,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为84.3%。
8,检验_白球比 → 检验_C反应蛋白 → 药物_复方鲜竹沥液,0.1188,0.0613,0.1792,0.0314,0.0378,-0.0828,0.1519,0.0624,0.1565,0.0558,0.2758,0.0574,0.9277,92.8,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为92.8%。
9,检验_白球比 → 检验_C反应蛋白 → 疾病_低钾血症,0.1515,0.0934,0.2141,0.0329,0.0374,-0.0732,0.1572,0.0621,0.1889,0.0785,0.2927,0.0577,0.9074,90.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为90.7%。
10,检验_白球比 → 检验_C反应蛋白 → 检验_总蛋白,0.0892,0.0323,0.1444,0.0302,0.048,-0.0764,0.1606,0.0644,0.1372,0.0262,0.2477,0.0591,0.8756,87.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为87.6%。
11,检验_白球比 → 检验_前白蛋白 → 检验_胆碱酯酶,0.189,0.1323,0.2523,0.0326,0.0914,-0.0124,0.1906,0.0539,0.2805,0.1798,0.3848,0.055,0.6955,69.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为69.5%。
12,检验_白球比 → 检验_前白蛋白 → 检验_镁,0.1196,0.0683,0.1732,0.0284,0.0992,-0.0088,0.2126,0.0591,0.2187,0.1184,0.3215,0.055,0.5855,58.6,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为58.6%。
13,检验_白球比 → 检验_前白蛋白 → 检验_总胆红素,0.1475,0.0883,0.2031,0.0307,-0.0248,-0.1356,0.0832,0.059,0.1227,0.0197,0.2294,0.0572,1.6244,162.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为162.4%。
14,检验_白球比 → 检验_白蛋白 → 检验_总蛋白,0.1279,0.078,0.1817,0.0287,0.0099,-0.0911,0.1208,0.0555,0.1378,0.0346,0.246,0.0569,1.1411,114.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为114.1%。
15,检验_白球比 → 检验_血小板 → 药物_维生素C注射液,0.0391,0.0041,0.0748,0.0189,0.2079,0.0938,0.3166,0.0599,0.247,0.1415,0.354,0.0571,0.1685,16.8,直接影响,强,正向中介,正向直接效应,弱中介,0.9885,是,0.9885,0.0115,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为16.8%。
16,检验_白球比 → 检验_血小板 → 检验_血小板比容,0.1033,0.057,0.1513,0.0255,-0.0005,-0.1044,0.1096,0.0565,0.1027,-0.0055,0.2036,0.0571,3.6603,366.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为366.0%。
17,检验_白球比 → 疾病_高脂血症 → 疾病_动脉硬化,-0.0897,-0.1349,-0.0464,0.025,0.0671,-0.0443,0.1631,0.0552,-0.0226,-0.1364,0.0812,0.058,0.1934,19.3,间接影响（中介效应）,强,负向中介,正向直接效应,弱中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为弱中介，中介比例为19.3%。
18,检验_白球比 → 疾病_高脂血症 → 药物_匹伐他汀钙片,-0.0728,-0.1138,-0.0352,0.0215,-0.0187,-0.1304,0.0853,0.057,-0.0915,-0.2039,0.0133,0.0584,-0.5655,-56.6,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-56.6%。
19,检验_白球比 → 疾病_高脂血症 → 药物_阿托伐他汀钙片,-0.0761,-0.1159,-0.0372,0.0217,0.1593,0.0486,0.2569,0.0567,0.0832,-0.0248,0.1959,0.0581,-0.4243,-42.4,直接影响,强,负向中介,正向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-42.4%。
20,检验_白球比 → 疾病_高脂血症 → 疾病_腔隙性脑梗死,-0.0435,-0.0757,-0.0142,0.017,-0.0469,-0.1527,0.0687,0.0585,-0.0904,-0.1914,0.0282,0.0581,1.1449,114.5,直接影响,强,负向中介,负向直接效应,完全中介,0.999,是,0.001,0.999,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为114.5%。
21,检验_白球比 → 疾病_高脂血症 → 疾病_前列腺增生,-0.0368,-0.0683,-0.0082,0.0164,-0.0185,-0.1261,0.0952,0.0599,-0.0553,-0.1645,0.0542,0.059,1.5686,156.9,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.997,是,0.003,0.997,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为156.9%。
22,检验_白球比 → 药物_氯化钾注射液 → 疾病_肺部感染,0.2443,0.1812,0.3188,0.0371,0.0579,-0.0435,0.1557,0.0524,0.3023,0.1975,0.414,0.0565,0.8285,82.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为82.9%。
23,检验_白球比 → 药物_氯化钾注射液 → 药物_维生素C注射液,0.2551,0.193,0.3314,0.038,-0.0086,-0.1073,0.0894,0.0521,0.2465,0.1452,0.36,0.0566,1.0819,108.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为108.2%。
24,检验_白球比 → 药物_氯化钾注射液 → 药物_氯化钠注射液,0.2304,0.1659,0.3028,0.0361,0.0813,-0.0099,0.1829,0.0517,0.3118,0.2126,0.4172,0.0549,0.7553,75.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为75.5%。
25,检验_白球比 → 药物_氯化钾注射液 → 检验_平均血红蛋白浓度,0.1433,0.0868,0.2012,0.0314,-0.1124,-0.2308,0.0058,0.0627,0.031,-0.0789,0.1433,0.0584,-1.6833,-168.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-168.3%。
26,检验_白球比 → 药物_氯化钾注射液 → 药物_盐酸氨溴索注射液,0.4016,0.3102,0.4989,0.0514,-0.0,-0.0352,0.0398,0.0199,0.4016,0.2978,0.4963,0.054,1.0022,100.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为100.2%。
27,检验_白球比 → 检验_钙 → 检验_嗜碱性粒细胞比率,-0.0126,-0.0419,0.0128,0.0144,-0.0908,-0.2047,0.0306,0.0619,-0.1033,-0.2179,0.0055,0.0607,-0.2869,-28.7,直接影响,强,负向中介,负向直接效应,部分中介,0.826,否,0.174,0.826,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-28.7%。
28,检验_白球比 → 药物_盐酸吗啡注射液 → 药物_盐酸布桂嗪注射液,0.0417,0.0125,0.0721,0.0164,0.0613,-0.048,0.166,0.0581,0.103,-0.0036,0.207,0.0577,0.6795,68.0,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为68.0%。
29,疾病_糖尿病 → 疾病_糖尿病性周围神经病 → 疾病_糖尿病性周围血管病,0.174,0.1154,0.2343,0.0324,0.0849,-0.0177,0.1889,0.0559,0.2589,0.1471,0.3595,0.0558,0.7001,70.0,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为70.0%。
30,疾病_糖尿病 → 疾病_糖尿病性周围神经病 → 疾病_糖尿病性视网膜病变,0.131,0.0827,0.1889,0.0287,0.0386,-0.0744,0.1466,0.0599,0.1696,0.0713,0.2837,0.0574,0.9095,90.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为90.9%。
31,疾病_糖尿病 → 疾病_糖尿病性周围神经病 → 疾病_高尿酸血症,0.1105,0.0621,0.1587,0.0271,0.1426,0.0318,0.25,0.0584,0.2532,0.1493,0.3504,0.055,0.4576,45.8,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为45.8%。
32,疾病_糖尿病 → 疾病_糖尿病性周围神经病 → 药物_甲钴胺片,0.0946,0.0468,0.1497,0.0268,0.034,-0.0805,0.1449,0.0609,0.1287,0.0125,0.2279,0.0582,2.5736,257.4,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为257.4%。
33,疾病_糖尿病 → 检验_葡萄糖 → 疾病_肝囊肿,-0.0797,-0.135,-0.0249,0.0292,-0.1144,-0.23,0.0026,0.0626,-0.1941,-0.3024,-0.0936,0.0562,0.4581,45.8,直接影响,强,负向中介,负向直接效应,部分中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为45.8%。
34,疾病_糖尿病 → 检验_葡萄糖 → 药物_地西泮注射液,0.0738,0.0181,0.1327,0.0311,-0.0338,-0.1544,0.0862,0.0641,0.0401,-0.0626,0.1531,0.0573,1.345,134.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.99,是,0.99,0.01,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为134.5%。
35,疾病_糖尿病 → 检验_葡萄糖 → 药物_碳酸钙片,-0.0066,-0.0639,0.0444,0.0289,-0.0036,-0.1284,0.1229,0.0659,-0.0102,-0.1162,0.1031,0.0581,-0.2236,-22.4,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,0.5865,否,0.4135,0.5865,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-22.4%。
36,疾病_糖尿病 → 药物_甲钴胺分散片 → 药物_卡维地洛片,0.0844,0.0442,0.1314,0.0239,0.0174,-0.0916,0.1264,0.0589,0.1018,-0.0002,0.2106,0.0585,1.1606,116.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为116.1%。
37,疾病_糖尿病 → 药物_阿卡波糖片 → 疾病_非毒性单个甲状腺结节,0.1209,0.0674,0.1789,0.03,0.0317,-0.0772,0.1523,0.0614,0.1526,0.0491,0.2569,0.057,0.9441,94.4,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为94.4%。
38,疾病_糖尿病 → 药物_阿卡波糖片 → 药物_精蛋白生物合成人胰岛素注射液,0.0806,0.0259,0.1374,0.0297,0.0518,-0.0652,0.1691,0.0626,0.1324,0.0159,0.2312,0.0574,0.761,76.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为76.1%。
39,疾病_糖尿病 → 药物_阿卡波糖片 → 检验_谷草转氨酶,0.1004,0.0444,0.1578,0.0299,-0.1204,-0.251,-0.0158,0.0617,-0.02,-0.1292,0.0821,0.0567,-5.8122,-581.2,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-581.2%。
40,疾病_糖尿病 → 药物_阿卡波糖片 → 疾病_糖尿病性周围神经病,0.1177,0.0621,0.1704,0.029,0.2563,0.1375,0.3633,0.0586,0.374,0.2597,0.4703,0.0552,0.3203,32.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为32.0%。
41,疾病_糖尿病 → 药物_阿卡波糖片 → 疾病_泌尿系感染,0.1203,0.0654,0.1783,0.0299,-0.0095,-0.1287,0.1007,0.0616,0.1108,0.0103,0.2246,0.0568,3.4447,344.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为344.5%。
42,疾病_糖尿病 → 检验_尿酸 → 疾病_高尿酸血症,0.0311,0.0053,0.0565,0.0143,0.2226,0.1126,0.3318,0.0587,0.2537,0.1508,0.3677,0.0585,0.1287,12.9,直接影响,强,正向中介,正向直接效应,弱中介,0.999,是,0.999,0.001,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为12.9%。
43,疾病_糖尿病 → 检验_尿酸 → 疾病_重度骨质疏松,0.004,-0.015,0.0254,0.0101,-0.0112,-0.1195,0.1119,0.0613,-0.0072,-0.1155,0.1116,0.0602,-0.1231,-12.3,直接影响,强,正向中介,负向直接效应,弱中介,0.67,否,0.67,0.33,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-12.3%。
44,疾病_糖尿病 → 检验_尿酸 → 检验_钾,0.0276,0.0037,0.0551,0.0137,-0.0084,-0.1138,0.1098,0.0598,0.0192,-0.0871,0.1337,0.0596,0.0358,3.6,间接影响（中介效应）,强,正向中介,负向直接效应,弱中介,0.9945,是,0.9945,0.0055,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为弱中介，中介比例为3.6%。
45,疾病_糖尿病 → 检验_尿酸 → 疾病_慢性胃炎,-0.015,-0.038,0.003,0.0111,-0.1059,-0.2051,0.0109,0.0574,-0.1209,-0.2293,-0.0163,0.0571,0.095,9.5,直接影响,强,负向中介,负向直接效应,弱中介,0.9415,否,0.0585,0.9415,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为9.5%。
46,疾病_糖尿病 → 检验_尿酸 → 药物_劳拉西泮片,0.0094,-0.0089,0.0315,0.0108,-0.0722,-0.1871,0.0426,0.0622,-0.0628,-0.1779,0.0438,0.0613,0.0675,6.7,直接影响,强,正向中介,负向直接效应,弱中介,0.8235,否,0.8235,0.1765,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为6.7%。
47,疾病_糖尿病 → 疾病_肝囊肿 → 疾病_结肠息肉,-0.0449,-0.0754,-0.0151,0.0167,-0.0453,-0.1551,0.0687,0.0599,-0.0902,-0.2014,0.0167,0.0602,-2.1127,-211.3,直接影响,强,负向中介,负向直接效应,完全中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-211.3%。
48,检验_淋巴细胞数量 → 检验_淋巴细胞比率 → 检验_中性粒细胞比率,0.2864,0.2165,0.3663,0.0398,0.0214,-0.0724,0.1069,0.0487,0.3078,0.2082,0.4111,0.0538,0.9498,95.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为95.0%。
49,检验_淋巴细胞数量 → 检验_淋巴细胞比率 → 药物_维生素B6注射液,0.0772,0.0247,0.1325,0.0294,-0.0612,-0.1829,0.0637,0.0649,0.0159,-0.0969,0.1182,0.0581,-2.7401,-274.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-274.0%。
50,检验_淋巴细胞数量 → 检验_直接胆红素 → 检验_总胆汁酸,0.0762,0.0383,0.119,0.0221,0.0568,-0.0554,0.1679,0.0598,0.133,0.0277,0.2529,0.0588,0.9031,90.3,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为90.3%。
51,检验_淋巴细胞数量 → 检验_直接胆红素 → 检验_碱性磷酸酶,0.0686,0.0333,0.1066,0.0201,0.2713,0.1642,0.3752,0.0562,0.3398,0.2421,0.446,0.0553,0.2063,20.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为20.6%。
52,检验_淋巴细胞数量 → 检验_直接胆红素 → 药物_盐酸羟考酮缓释片,0.0816,0.0377,0.1224,0.0228,0.1789,0.0676,0.2798,0.0566,0.2605,0.1588,0.3707,0.0569,0.3288,32.9,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为32.9%。
53,检验_淋巴细胞数量 → 检验_直接胆红素 → 检验_总胆红素,0.1604,0.0991,0.2272,0.0352,-0.1148,-0.2034,-0.0189,0.0497,0.0456,-0.0608,0.1569,0.0584,1.5046,150.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为150.5%。
54,检验_淋巴细胞数量 → 检验_直接胆红素 → 疾病_泌尿系感染,-0.0386,-0.0746,-0.0092,0.0177,0.1169,-0.006,0.2249,0.0616,0.0783,-0.0309,0.1835,0.0593,14.8486,1484.9,直接影响,强,负向中介,正向直接效应,完全中介,0.988,是,0.012,0.988,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为1484.9%。
55,疾病_低蛋白血症 → 检验_白球比 → 检验_C反应蛋白,0.1633,0.0962,0.2321,0.0365,0.2703,0.1627,0.3871,0.0604,0.4336,0.3358,0.5302,0.0521,0.3813,38.1,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.1%。
56,疾病_低蛋白血症 → 检验_白球比 → 检验_前白蛋白,0.1121,0.0496,0.1802,0.0353,0.3466,0.2413,0.4687,0.0607,0.4587,0.3611,0.5509,0.0521,0.247,24.7,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为24.7%。
57,疾病_低蛋白血症 → 检验_白球比 → 检验_白蛋白,0.15,0.0868,0.227,0.0381,0.0441,-0.0789,0.1716,0.0664,0.194,0.0756,0.2959,0.0587,0.8689,86.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为86.9%。
58,疾病_低蛋白血症 → 检验_白球比 → 检验_血小板,0.1391,0.0756,0.2169,0.0381,0.0626,-0.0601,0.1927,0.0667,0.2017,0.0921,0.3033,0.0557,0.7636,76.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为76.4%。
59,疾病_低蛋白血症 → 检验_白球比 → 疾病_高脂血症,-0.0966,-0.1626,-0.0181,0.0383,-0.105,-0.2354,0.0261,0.0698,-0.2016,-0.3046,-0.0922,0.0584,0.5379,53.8,直接影响,强,负向中介,负向直接效应,部分中介,0.993,是,0.007,0.993,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为53.8%。
60,疾病_低蛋白血症 → 检验_白球比 → 药物_氯化钾注射液,0.2338,0.1634,0.3109,0.039,-0.0309,-0.1463,0.0867,0.063,0.2029,0.1009,0.3075,0.0561,1.2698,127.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为127.0%。
61,疾病_低蛋白血症 → 检验_白球比 → 检验_钙,0.0825,0.0144,0.1491,0.0364,0.1577,0.0352,0.2795,0.0665,0.2403,0.132,0.3388,0.0559,0.3659,36.6,直接影响,强,正向中介,正向直接效应,部分中介,0.9895,是,0.9895,0.0105,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为36.6%。
62,疾病_低蛋白血症 → 检验_白球比 → 药物_盐酸吗啡注射液,0.1259,0.0528,0.2002,0.0391,-0.0303,-0.1548,0.09,0.0666,0.0956,-0.0163,0.1973,0.0561,1.1436,114.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为114.4%。
63,疾病_低蛋白血症 → 检验_C反应蛋白 → 药物_复方鲜竹沥液,0.1168,0.0647,0.1784,0.0305,0.033,-0.0849,0.1545,0.0628,0.1499,0.0376,0.2541,0.0572,0.6943,69.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为69.4%。
64,疾病_低蛋白血症 → 检验_C反应蛋白 → 疾病_低钾血症,0.1629,0.1021,0.2231,0.033,-0.055,-0.1671,0.0691,0.0626,0.1079,-0.0005,0.2156,0.0583,0.693,69.3,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为69.3%。
65,疾病_低蛋白血症 → 检验_C反应蛋白 → 检验_总蛋白,0.0753,0.0179,0.1252,0.0286,0.1112,0.0008,0.2369,0.0633,0.1865,0.0858,0.2951,0.0559,0.4598,46.0,直接影响,强,正向中介,正向直接效应,部分中介,0.998,是,0.998,0.002,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为46.0%。
66,检验_中性粒细胞数量 → 检验_白细胞 → 药物_二羟丙茶碱注射液,-0.0695,-0.1379,-0.0064,0.0353,0.1157,0.0022,0.257,0.0677,0.0461,-0.0601,0.1498,0.0569,-0.4073,-40.7,直接影响,强,负向中介,正向直接效应,部分中介,0.976,是,0.024,0.976,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-40.7%。
67,检验_中性粒细胞数量 → 检验_镁 → 检验_碳酸氢盐,0.0351,0.0089,0.0691,0.0161,-0.0856,-0.1961,0.0183,0.0578,-0.0504,-0.1542,0.0561,0.0581,-0.6773,-67.7,直接影响,强,正向中介,负向直接效应,部分中介,0.9945,是,0.9945,0.0055,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-67.7%。
68,检验_中性粒细胞数量 → 药物_苯磺酸氨氯地平片 → 疾病_高血压,-0.0304,-0.0586,-0.0034,0.0152,-0.0327,-0.1317,0.0757,0.0552,-0.0631,-0.1651,0.0452,0.0569,-0.1941,-19.4,直接影响,强,负向中介,负向直接效应,弱中介,0.9895,是,0.0105,0.9895,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-19.4%。
69,药物_螺内酯片 → 药物_酒石酸美托洛尔片 → 药物_富马酸比索洛尔片,-0.0397,-0.0845,0.0039,0.0241,0.0345,-0.0887,0.1502,0.0649,-0.0052,-0.1132,0.1109,0.0605,0.6806,68.1,间接影响（中介效应）,强,负向中介,正向直接效应,部分中介,0.962,是,0.038,0.962,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为68.1%。
70,药物_螺内酯片 → 药物_酒石酸美托洛尔片 → 药物_硝苯地平缓释片,0.0782,0.0288,0.1258,0.0258,-0.1291,-0.2451,-0.014,0.0623,-0.0509,-0.1632,0.0565,0.0583,-1.7113,-171.1,直接影响,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-171.1%。
71,检验_氯 → 检验_钠 → 药物_重组人促红素注射液,0.1187,0.0627,0.1753,0.0305,0.2495,0.1228,0.348,0.0596,0.3682,0.2645,0.4634,0.0546,0.3287,32.9,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为32.9%。
72,检验_氯 → 检验_钠 → 检验_淋巴细胞比率,0.1002,0.0429,0.1556,0.0304,0.1967,0.0727,0.309,0.0634,0.2969,0.1929,0.4048,0.0569,0.3503,35.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为35.0%。
73,检验_氯 → 检验_钠 → 检验_葡萄糖,0.122,0.0628,0.1842,0.0329,-0.0549,-0.1761,0.066,0.0646,0.0672,-0.037,0.181,0.058,3.4496,345.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为345.0%。
74,检验_氯 → 药物_单硝酸异山梨酯缓释片 → 药物_裸花紫珠分散片,0.0532,0.0181,0.0883,0.0191,-0.0872,-0.196,0.0217,0.0589,-0.034,-0.1541,0.0633,0.0591,-2.8829,-288.3,直接影响,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-288.3%。
75,药物_重组人促红素注射液 → 疾病_尿毒症 → 检验_胆碱酯酶,0.2436,0.0306,0.4426,0.1093,0.2251,0.0152,0.463,0.1196,0.4687,0.3797,0.5653,0.0505,0.5256,52.6,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.985,是,0.985,0.015,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为52.6%。
76,药物_重组人促红素注射液 → 疾病_尿毒症 → 检验_谷丙转氨酶,0.2249,0.0041,0.4316,0.1142,0.2186,-0.0209,0.4398,0.123,0.4434,0.3402,0.5378,0.053,0.5127,51.3,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.977,是,0.977,0.023,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为51.3%。
77,药物_重组人促红素注射液 → 疾病_尿毒症 → 疾病_高血压,-0.3304,-0.567,-0.1093,0.1228,0.1375,-0.1204,0.3838,0.1352,-0.1929,-0.3019,-0.0899,0.0566,1.9069,190.7,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.9965,是,0.0035,0.9965,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为190.7%。
78,药物_重组人促红素注射液 → 疾病_尿毒症 → 检验_淋巴细胞数量,0.2074,-0.0094,0.4356,0.1188,0.1648,-0.073,0.4052,0.1278,0.3721,0.2698,0.4721,0.053,0.5672,56.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.958,是,0.958,0.042,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为56.7%。
79,药物_重组人促红素注射液 → 疾病_尿毒症 → 检验_肌酐,0.1985,-0.0218,0.4183,0.1195,0.1401,-0.0982,0.4076,0.1324,0.3386,0.2343,0.4368,0.0542,0.6037,60.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.9545,是,0.9545,0.0455,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为60.4%。
80,药物_重组人促红素注射液 → 疾病_尿毒症 → 检验_红细胞平均体积,0.3775,0.156,0.6095,0.1206,-0.0762,-0.3266,0.1728,0.1323,0.3013,0.1947,0.4076,0.056,1.3017,130.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为130.2%。
81,药物_重组人促红素注射液 → 检验_磷 → 药物_碳酸钙片,0.0553,0.0096,0.1047,0.0255,0.0689,-0.0434,0.1955,0.0624,0.1242,0.0183,0.2357,0.0576,0.6876,68.8,直接影响,强,正向中介,正向直接效应,部分中介,0.9915,是,0.9915,0.0085,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为68.8%。
82,药物_重组人促红素注射液 → 检验_钠 → 检验_淋巴细胞比率,0.103,0.0519,0.1523,0.0269,0.0951,-0.0131,0.2205,0.0617,0.1981,0.0906,0.3102,0.0588,0.5605,56.0,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为56.0%。
83,药物_重组人促红素注射液 → 检验_钠 → 检验_葡萄糖,0.0709,0.0299,0.1208,0.0246,0.1351,0.0165,0.2472,0.0624,0.206,0.1025,0.3191,0.0586,0.3702,37.0,直接影响,强,正向中介,正向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为37.0%。
84,药物_重组人促红素注射液 → 检验_钠 → 检验_氯,0.139,0.0854,0.1924,0.0288,0.2298,0.1271,0.3322,0.0547,0.3688,0.2584,0.4627,0.0537,0.3827,38.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.3%。
85,药物_重组人促红素注射液 → 检验_谷丙转氨酶 → 检验_谷草转氨酶,0.1223,0.0672,0.1804,0.0302,0.1496,0.0342,0.2633,0.061,0.2719,0.1622,0.369,0.0561,0.4702,47.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为47.0%。
86,药物_重组人促红素注射液 → 检验_谷丙转氨酶 → 检验_谷草/谷丙,0.1208,0.0571,0.1786,0.0323,-0.0349,-0.1474,0.0858,0.0635,0.086,-0.0159,0.2002,0.0581,1.3182,131.8,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为131.8%。
87,药物_重组人促红素注射液 → 检验_谷丙转氨酶 → 疾病_肺恶性肿瘤,0.0928,0.0362,0.1484,0.0303,-0.1493,-0.2666,-0.0309,0.064,-0.0565,-0.1641,0.0509,0.0575,-0.4409,-44.1,直接影响,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-44.1%。
88,疾病_冠状动脉粥样硬化性心脏病 → 药物_盐酸曲美他嗪片 → 药物_硫酸氢氯吡格雷片,0.1888,0.1303,0.2528,0.0326,0.1667,0.0673,0.2714,0.0548,0.3555,0.2552,0.4622,0.0553,0.5405,54.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为54.1%。
89,疾病_冠状动脉粥样硬化性心脏病 → 药物_盐酸曲美他嗪片 → 疾病_低蛋白血症,0.1283,0.0781,0.1843,0.0285,0.1308,0.0242,0.245,0.0594,0.259,0.1585,0.3707,0.0569,0.5201,52.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为52.0%。
90,疾病_冠状动脉粥样硬化性心脏病 → 药物_盐酸曲美他嗪片 → 药物_阿卡波糖片,0.1223,0.0623,0.1728,0.0292,0.1325,0.0238,0.252,0.061,0.2548,0.1491,0.359,0.0575,0.5043,50.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为50.4%。
91,疾病_冠状动脉粥样硬化性心脏病 → 药物_盐酸曲美他嗪片 → 疾病_陈旧性脑梗死,0.1721,0.1127,0.2361,0.0331,0.142,0.0391,0.254,0.0563,0.3141,0.207,0.4191,0.0561,0.5614,56.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为56.1%。
92,疾病_冠状动脉粥样硬化性心脏病 → 疾病_不稳定性心绞痛 → 疾病_心功能,0.1442,0.0897,0.2019,0.0301,0.1336,0.0234,0.2358,0.0575,0.2778,0.1707,0.3713,0.0543,0.5382,53.8,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为53.8%。
93,疾病_冠状动脉粥样硬化性心脏病 → 疾病_不稳定性心绞痛 → 疾病_反流性食管炎,0.115,0.0597,0.1686,0.0294,0.0711,-0.0398,0.1914,0.0614,0.1861,0.0768,0.2936,0.0577,0.6952,69.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为69.5%。
94,疾病_冠状动脉粥样硬化性心脏病 → 疾病_不稳定性心绞痛 → 药物_盐酸曲美他嗪片,0.1828,0.1245,0.2404,0.0317,0.231,0.1392,0.3328,0.0517,0.4138,0.3156,0.508,0.0515,0.4458,44.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为44.6%。
95,疾病_冠状动脉粥样硬化性心脏病 → 药物_单硝酸异山梨酯片 → 疾病_类风湿性关节炎,0.1232,0.0711,0.1802,0.0291,-0.0165,-0.1365,0.0968,0.0619,0.1067,-0.0007,0.2207,0.0588,0.5867,58.7,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为58.7%。
96,疾病_冠状动脉粥样硬化性心脏病 → 药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片,0.0442,0.0132,0.075,0.0169,0.3122,0.2145,0.4221,0.0545,0.3564,0.2585,0.4617,0.0541,0.1262,12.6,直接影响,强,正向中介,正向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为12.6%。
97,疾病_冠状动脉粥样硬化性心脏病 → 药物_阿托伐他汀钙片 → 疾病_心律失常,-0.0176,-0.0423,0.0079,0.0134,0.1435,0.0255,0.2529,0.0599,0.1259,0.0184,0.2333,0.058,-0.258,-25.8,直接影响,强,负向中介,正向直接效应,部分中介,0.922,否,0.078,0.922,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-25.8%。
98,疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症 → 检验_胆碱酯酶,-0.0505,-0.0995,0.0001,0.0273,0.0547,-0.037,0.1586,0.0526,0.0042,-0.1001,0.1199,0.0584,0.3126,31.3,直接影响,强,负向中介,正向直接效应,部分中介,0.9755,是,0.0245,0.9755,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为31.3%。
99,疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症 → 检验_谷丙转氨酶,-0.0476,-0.0991,-0.0035,0.0258,0.0495,-0.0609,0.1459,0.0542,0.0019,-0.1043,0.1103,0.0584,-0.4774,-47.7,直接影响,强,负向中介,正向直接效应,部分中介,0.973,是,0.027,0.973,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-47.7%。
100,疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症 → 疾病_高血压,0.0231,-0.0012,0.0501,0.0138,0.1932,0.0832,0.2946,0.0564,0.2162,0.1063,0.326,0.0579,0.1118,11.2,直接影响,强,正向中介,正向直接效应,弱中介,0.9685,是,0.9685,0.0315,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为11.2%。
101,疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症 → 检验_淋巴细胞数量,-0.04,-0.0817,0.0006,0.0222,0.0742,-0.0215,0.183,0.0538,0.0343,-0.0789,0.1332,0.0573,8.1144,811.4,直接影响,强,负向中介,正向直接效应,完全中介,0.9685,是,0.0315,0.9685,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为811.4%。
102,疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症 → 检验_肌酐,-0.0383,-0.075,0.0044,0.0214,0.1373,0.0287,0.2427,0.0575,0.0989,-0.0153,0.2092,0.0606,-0.669,-66.9,直接影响,强,负向中介,正向直接效应,部分中介,0.971,是,0.029,0.971,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-66.9%。
103,疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症 → 检验_红细胞平均体积,-0.0343,-0.0702,0.0019,0.0196,-0.0938,-0.1974,0.0056,0.0543,-0.1281,-0.2313,-0.0252,0.0566,1.1356,113.6,直接影响,强,负向中介,负向直接效应,完全中介,0.9685,是,0.0315,0.9685,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为113.6%。
104,检验_C反应蛋白 → 疾病_低钾血症 → 疾病_心功能,0.0563,0.0077,0.0973,0.0236,0.1046,-0.0136,0.2089,0.0594,0.1609,0.0532,0.2627,0.0554,0.4142,41.4,直接影响,强,正向中介,正向直接效应,部分中介,0.9945,是,0.9945,0.0055,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为41.4%。
105,检验_C反应蛋白 → 疾病_低钾血症 → 检验_钾,0.0997,0.0542,0.1487,0.0256,0.0788,-0.039,0.1856,0.0607,0.1785,0.0641,0.2802,0.0584,0.6247,62.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为62.5%。
106,检验_C反应蛋白 → 检验_总蛋白 → 检验_钙,0.0557,0.0224,0.0911,0.0186,0.1563,0.0525,0.266,0.0563,0.212,0.1041,0.315,0.0564,0.2824,28.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为28.2%。
107,检验_C反应蛋白 → 检验_总蛋白 → 检验_球蛋白,0.0741,0.0352,0.1199,0.0231,-0.1434,-0.2448,-0.0327,0.0565,-0.0693,-0.1817,0.0353,0.0585,-0.5525,-55.3,直接影响,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-55.3%。
108,检验_C反应蛋白 → 检验_总蛋白 → 检验_白蛋白,0.0872,0.0437,0.1365,0.0253,0.1497,0.0573,0.2503,0.0529,0.237,0.1344,0.3352,0.0552,0.3837,38.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.4%。
109,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 药物_贞芪扶正,0.1196,0.0711,0.1728,0.0279,-0.1937,-0.2992,-0.0854,0.0571,-0.0741,-0.1768,0.0337,0.0579,-0.4533,-45.3,直接影响,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-45.3%。
110,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 疾病_恶性肿瘤维持性化学治疗,0.1126,0.0667,0.1671,0.027,-0.1299,-0.2379,-0.0273,0.0574,-0.0173,-0.124,0.0815,0.0568,6.798,679.8,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为679.8%。
111,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 疾病_胆囊结石,0.0029,-0.0338,0.0362,0.0187,-0.0891,-0.2101,0.0204,0.0622,-0.0862,-0.1963,0.026,0.0593,-0.1795,-18.0,直接影响,强,正向中介,负向直接效应,弱中介,0.569,否,0.569,0.431,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-18.0%。
112,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 疾病_贫血,0.072,0.0331,0.113,0.0219,-0.0601,-0.166,0.0523,0.0598,0.012,-0.093,0.1175,0.0569,-0.8616,-86.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-86.2%。
113,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 疾病_混合痔,-0.057,-0.0955,-0.0156,0.0212,-0.0232,-0.1377,0.0875,0.0611,-0.0802,-0.1916,0.021,0.0588,2.3589,235.9,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.9985,是,0.0015,0.9985,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为235.9%。
114,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 疾病_糖尿病性周围神经病,-0.0348,-0.0751,-0.002,0.0196,0.1634,0.0512,0.284,0.0617,0.1285,0.0202,0.2392,0.0588,0.0666,6.7,直接影响,强,负向中介,正向直接效应,弱中介,0.969,是,0.031,0.969,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为6.7%。
115,疾病_不稳定性心绞痛 → 疾病_反流性食管炎 → 药物_琥珀酸亚铁片,-0.0087,-0.046,0.0245,0.0189,-0.0398,-0.1528,0.0742,0.0613,-0.0485,-0.1556,0.0599,0.0577,0.1098,11.0,直接影响,强,负向中介,负向直接效应,弱中介,0.684,否,0.316,0.684,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为11.0%。
116,疾病_不稳定性心绞痛 → 药物_盐酸曲美他嗪片 → 药物_硫酸氢氯吡格雷片,0.2407,0.172,0.3141,0.0383,0.1399,0.0355,0.2526,0.0582,0.3806,0.2816,0.4817,0.0531,0.6427,64.3,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为64.3%。
117,疾病_不稳定性心绞痛 → 药物_盐酸曲美他嗪片 → 疾病_低蛋白血症,0.1715,0.1037,0.2449,0.0376,0.0857,-0.0404,0.1985,0.0639,0.2573,0.1532,0.3622,0.0564,0.7339,73.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为73.4%。
118,疾病_不稳定性心绞痛 → 药物_盐酸曲美他嗪片 → 药物_阿卡波糖片,0.187,0.1164,0.2672,0.0398,0.0107,-0.1129,0.1338,0.065,0.1976,0.0912,0.3077,0.0572,1.0568,105.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为105.7%。
119,疾病_不稳定性心绞痛 → 药物_盐酸曲美他嗪片 → 疾病_陈旧性脑梗死,0.2336,0.1623,0.311,0.0393,0.0801,-0.0269,0.2079,0.0615,0.3137,0.2088,0.4106,0.0545,0.7654,76.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为76.5%。
120,疾病_混合痔 → 疾病_肛乳头肥大 → 检验_谷草/谷丙,0.0864,0.005,0.1663,0.0427,-0.0623,-0.1968,0.0724,0.0721,0.0241,-0.0869,0.1301,0.0587,0.3849,38.5,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.9795,是,0.9795,0.0205,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为38.5%。
121,药物_盐酸羟考酮缓释片 → 检验_碱性磷酸酶 → 检验_转肽酶,0.1856,0.1257,0.2483,0.0333,0.1271,0.0202,0.2325,0.056,0.3127,0.2105,0.4165,0.055,0.6088,60.9,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为60.9%。
122,药物_盐酸羟考酮缓释片 → 检验_碱性磷酸酶 → 药物_盐酸吗啡注射液,0.0651,0.0175,0.1189,0.0275,0.3111,0.1945,0.4177,0.0594,0.3762,0.279,0.4775,0.0533,0.1766,17.7,直接影响,强,正向中介,正向直接效应,弱中介,0.9965,是,0.9965,0.0035,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为17.7%。
123,药物_盐酸羟考酮缓释片 → 检验_碱性磷酸酶 → 检验_尿酸,0.0846,0.0286,0.1393,0.0295,0.1002,-0.0103,0.2322,0.0637,0.1848,0.0835,0.2985,0.0576,0.6013,60.1,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为60.1%。
124,药物_盐酸羟考酮缓释片 → 检验_碱性磷酸酶 → 疾病_肝功能异常,0.0891,0.0364,0.1472,0.0297,0.0985,-0.0118,0.2301,0.0636,0.1876,0.0852,0.3004,0.0575,1.0996,110.0,直接影响,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为110.0%。
125,疾病_肾性贫血 → 药物_碳酸氢钠片 → 检验_磷,0.0844,0.0275,0.1332,0.0287,0.0077,-0.1167,0.1294,0.0656,0.0921,-0.0263,0.1985,0.06,1.0489,104.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为104.9%。
126,疾病_肾性贫血 → 药物_骨化三醇胶丸 → 疾病_类风湿性关节炎,0.1097,0.0588,0.1602,0.0273,-0.127,-0.2415,-0.0283,0.0565,-0.0173,-0.1194,0.1016,0.0587,-9.0664,-906.6,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-906.6%。
127,疾病_肾性贫血 → 药物_骨化三醇胶丸 → 药物_碳酸钙片,0.0915,0.0474,0.1355,0.0241,0.2282,0.1221,0.3241,0.0546,0.3197,0.2098,0.4189,0.056,0.2919,29.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为29.2%。
128,疾病_肾性贫血 → 药物_骨化三醇胶丸 → 药物_酒石酸美托洛尔片,0.071,0.0323,0.1093,0.0212,0.046,-0.0595,0.1507,0.0558,0.117,0.0138,0.2197,0.0555,0.6767,67.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为67.7%。
129,疾病_肾性贫血 → 药物_琥珀酸亚铁片 → 药物_叶酸片,0.1263,0.0716,0.1732,0.0278,0.1799,0.073,0.2742,0.0538,0.3062,0.2017,0.4074,0.0547,0.4218,42.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为42.2%。
130,疾病_肾性贫血 → 药物_琥珀酸亚铁片 → 疾病_糖尿病性周围血管病,0.1046,0.0588,0.155,0.0258,-0.1436,-0.2554,-0.0306,0.0599,-0.0391,-0.1604,0.062,0.0595,-28.0984,-2809.8,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-2809.8%。
131,疾病_糖尿病性周围神经病 → 疾病_糖尿病性周围血管病 → 疾病_血糖控制不佳,0.2592,0.1904,0.3367,0.0392,0.0159,-0.0929,0.1274,0.0582,0.2751,0.176,0.3829,0.055,0.9773,97.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为97.7%。
132,疾病_糖尿病性周围神经病 → 疾病_糖尿病性视网膜病变 → 疾病_白内障,0.0858,0.038,0.1334,0.0253,0.1195,0.0017,0.2304,0.0596,0.2053,0.1002,0.3096,0.0563,0.4708,47.1,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为47.1%。
133,疾病_糖尿病性周围神经病 → 疾病_糖尿病性视网膜病变 → 药物_厄贝沙坦片,0.0692,0.0265,0.1191,0.0248,0.111,-0.0033,0.2251,0.0624,0.1802,0.0768,0.2853,0.0581,0.5009,50.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为50.1%。
134,疾病_糖尿病性周围神经病 → 疾病_高尿酸血症 → 药物_碳酸氢钠片,0.1254,0.0767,0.1803,0.0279,0.0714,-0.0298,0.1973,0.0602,0.1968,0.0947,0.3111,0.0583,0.7037,70.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为70.4%。
135,疾病_糖尿病性周围神经病 → 疾病_高尿酸血症 → 药物_硝苯地平控释片,0.1102,0.067,0.1636,0.0263,0.105,-0.0077,0.2116,0.0596,0.2153,0.1109,0.3234,0.0571,0.5516,55.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为55.2%。
136,疾病_高尿酸血症 → 药物_碳酸氢钠片 → 检验_磷,0.0916,0.0427,0.1421,0.0266,-0.0867,-0.2058,0.0286,0.0628,0.0049,-0.0988,0.1239,0.0597,-5.7747,-577.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-577.5%。
137,疾病_高尿酸血症 → 药物_硝苯地平控释片 → 药物_厄贝沙坦片,0.0881,0.0402,0.1363,0.0257,0.1544,0.0424,0.2651,0.0598,0.2425,0.1421,0.3513,0.0561,0.3837,38.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.4%。
138,疾病_高尿酸血症 → 药物_硝苯地平控释片 → 药物_厄贝沙坦氢氯噻嗪片,0.0961,0.0511,0.1469,0.0252,0.0988,-0.0167,0.2055,0.0604,0.1949,0.0923,0.302,0.0574,0.5426,54.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为54.3%。
139,疾病_高血压 → 药物_阿司匹林肠溶片 → 疾病_重度骨质疏松,-0.0501,-0.0898,-0.0167,0.0197,0.1811,0.072,0.2962,0.0606,0.131,0.0222,0.2321,0.0567,-0.4776,-47.8,直接影响,强,负向中介,正向直接效应,部分中介,0.9985,是,0.0015,0.9985,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-47.8%。
140,疾病_高血压 → 药物_阿司匹林肠溶片 → 药物_阿托伐他汀钙片,0.0916,0.0463,0.1359,0.0244,0.0762,-0.0329,0.1911,0.0607,0.1678,0.0598,0.2775,0.0589,1.0762,107.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为107.6%。
141,疾病_高血压 → 药物_阿司匹林肠溶片 → 药物_厄贝沙坦片,0.0557,0.0164,0.0959,0.0214,0.0724,-0.0395,0.1783,0.0585,0.1281,0.0306,0.2353,0.056,0.5739,57.4,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为57.4%。
142,疾病_高血压 → 药物_富马酸比索洛尔片 → 药物_硝苯地平缓释片,0.0568,0.0245,0.0941,0.0188,0.0732,-0.0492,0.1779,0.0592,0.1301,0.0197,0.2421,0.0597,-0.734,-73.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-73.4%。
143,疾病_高血压 → 药物_富马酸比索洛尔片 → 疾病_心律失常,0.0402,0.0115,0.0751,0.0171,0.0257,-0.0907,0.1449,0.0613,0.066,-0.0444,0.1825,0.06,1.0899,109.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.9965,是,0.9965,0.0035,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为109.0%。
144,疾病_高血压 → 药物_富马酸比索洛尔片 → 药物_甲钴胺片,0.0138,-0.0137,0.0432,0.0149,0.0184,-0.1022,0.1276,0.0606,0.0322,-0.0769,0.1401,0.0579,-1.3464,-134.6,直接影响,强,正向中介,正向直接效应,完全中介,0.8465,否,0.8465,0.1535,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-134.6%。
145,疾病_高血压 → 药物_硝苯地平控释片 → 药物_厄贝沙坦片,0.0643,0.0243,0.1015,0.0209,0.0625,-0.0514,0.1578,0.0562,0.1268,0.0214,0.2295,0.0572,0.6854,68.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为68.5%。
146,疾病_高血压 → 药物_硝苯地平控释片 → 药物_厄贝沙坦氢氯噻嗪片,0.0637,0.0267,0.1024,0.0204,0.1075,0.0048,0.2121,0.0558,0.1712,0.0628,0.2736,0.0561,0.4284,42.8,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为42.8%。
147,疾病_高血压 → 药物_厄贝沙坦氢氯噻嗪片 → 疾病_低钾血症,0.0412,0.011,0.0708,0.0167,0.0627,-0.0492,0.1676,0.0581,0.1039,-0.0027,0.2153,0.0587,0.1342,13.4,直接影响,强,正向中介,正向直接效应,弱中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为13.4%。
148,疾病_高血压 → 疾病_糖尿病 → 疾病_糖尿病性周围神经病,0.0958,0.0512,0.1426,0.0247,0.0803,-0.0258,0.1792,0.056,0.1761,0.0664,0.2795,0.0576,0.5567,55.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为55.7%。
149,疾病_高血压 → 疾病_糖尿病 → 检验_葡萄糖,0.1176,0.0655,0.1726,0.0285,0.084,-0.0218,0.1847,0.0554,0.2016,0.0905,0.3015,0.0569,0.6315,63.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为63.1%。
150,疾病_高血压 → 疾病_糖尿病 → 药物_甲钴胺分散片,0.0736,0.0343,0.1161,0.0225,-0.0399,-0.1499,0.0681,0.0604,0.0337,-0.0745,0.1413,0.0602,-3.8396,-384.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-384.0%。
151,疾病_高血压 → 疾病_糖尿病 → 药物_阿卡波糖片,0.1078,0.057,0.1543,0.0264,0.1103,0.0073,0.2108,0.0551,0.2181,0.1173,0.3232,0.0559,0.5221,52.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为52.2%。
152,疾病_高血压 → 疾病_糖尿病 → 药物_盐酸二甲双胍片,0.0775,0.0371,0.1195,0.0222,0.1117,0.0002,0.2171,0.0584,0.1892,0.0828,0.2943,0.058,0.4791,47.9,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为47.9%。
153,疾病_高血压 → 疾病_糖尿病 → 检验_尿酸,0.0414,0.0086,0.0772,0.0184,0.0517,-0.0655,0.1641,0.0612,0.093,-0.0128,0.2049,0.0589,0.5933,59.3,直接影响,强,正向中介,正向直接效应,部分中介,0.9945,是,0.9945,0.0055,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为59.3%。
154,疾病_高血压 → 疾病_糖尿病 → 疾病_肝囊肿,-0.0632,-0.1011,-0.0263,0.0205,0.1451,0.0279,0.2549,0.0616,0.082,-0.0246,0.199,0.0604,-0.5906,-59.1,直接影响,强,负向中介,正向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-59.1%。
155,疾病_高血压 → 疾病_反流性食管炎 → 药物_贞芪扶正,0.0105,-0.025,0.0491,0.0199,-0.0811,-0.1919,0.0168,0.0557,-0.0706,-0.183,0.0346,0.0588,-0.4118,-41.2,直接影响,强,正向中介,负向直接效应,部分中介,0.708,否,0.708,0.292,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-41.2%。
156,疾病_高血压 → 疾病_反流性食管炎 → 疾病_恶性肿瘤维持性化学治疗,0.0098,-0.0259,0.0469,0.0196,0.0245,-0.0874,0.1264,0.0568,0.0343,-0.082,0.1427,0.0595,0.1566,15.7,直接影响,强,正向中介,正向直接效应,弱中介,0.7015,否,0.7015,0.2985,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为15.7%。
157,疾病_高血压 → 疾病_反流性食管炎 → 疾病_胆囊结石,-0.0007,-0.0084,0.0066,0.0038,0.0863,-0.0215,0.2078,0.0618,0.0856,-0.0285,0.2004,0.0617,-0.0013,-0.1,直接影响,强,负向中介,正向直接效应,弱中介,0.567,否,0.433,0.567,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-0.1%。
158,疾病_高血压 → 疾病_反流性食管炎 → 疾病_贫血,0.007,-0.016,0.0315,0.0128,-0.0437,-0.1606,0.0633,0.0594,-0.0366,-0.1503,0.0746,0.0605,0.0004,0.0,直接影响,强,正向中介,负向直接效应,弱中介,0.721,否,0.721,0.279,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为0.0%。
159,疾病_高血压 → 疾病_反流性食管炎 → 疾病_混合痔,-0.0058,-0.0265,0.0163,0.0113,-0.2625,-0.3609,-0.1504,0.0552,-0.2683,-0.3766,-0.164,0.0566,0.0205,2.1,直接影响,强,负向中介,负向直接效应,弱中介,0.705,否,0.295,0.705,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为2.1%。
160,疾病_高血压 → 疾病_反流性食管炎 → 疾病_糖尿病性周围神经病,-0.0023,-0.0132,0.0067,0.0053,0.1764,0.0718,0.2916,0.0585,0.1741,0.0702,0.2926,0.0586,-0.0197,-2.0,直接影响,强,负向中介,正向直接效应,弱中介,0.6795,否,0.3205,0.6795,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-2.0%。
161,疾病_高血压 → 疾病_反流性食管炎 → 药物_琥珀酸亚铁片,-0.0014,-0.0104,0.0066,0.0044,0.1222,0.0066,0.236,0.0614,0.1208,0.0067,0.2365,0.0615,-0.0054,-0.5,直接影响,强,负向中介,正向直接效应,弱中介,0.604,否,0.396,0.604,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-0.5%。
162,疾病_高血压 → 疾病_动脉硬化 → 疾病_慢性胃炎,0.0321,0.0081,0.0611,0.0146,-0.0578,-0.1608,0.0562,0.0576,-0.0257,-0.1261,0.095,0.058,-4.5163,-451.6,直接影响,强,正向中介,负向直接效应,完全中介,0.9945,是,0.9945,0.0055,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-451.6%。
163,疾病_高血压 → 疾病_动脉硬化 → 疾病_高脂血症,0.0518,0.0138,0.0908,0.021,0.191,0.0869,0.2918,0.0547,0.2428,0.1416,0.3575,0.0564,0.2209,22.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9955,是,0.9955,0.0045,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为22.1%。
164,疾病_高血压 → 疾病_脂肪肝 → 疾病_胆囊结石,0.0715,0.0334,0.1133,0.0225,0.0152,-0.0875,0.1283,0.0565,0.0867,-0.0183,0.1957,0.058,2.3924,239.2,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为239.2%。
165,疾病_高血压 → 疾病_脂肪肝 → 检验_C反应蛋白,-0.0509,-0.088,-0.0186,0.0186,0.1488,0.0279,0.2554,0.0593,0.098,-0.0165,0.2141,0.0605,-0.5781,-57.8,直接影响,强,负向中介,正向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-57.8%。
166,疾病_高血压 → 疾病_脂肪肝 → 疾病_糖尿病性周围血管病,0.0575,0.0243,0.0955,0.0196,0.0285,-0.0995,0.1282,0.0594,0.086,-0.0305,0.1974,0.0599,10.4035,1040.4,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为1040.4%。
167,疾病_高血压 → 疾病_脂肪肝 → 疾病_肺恶性肿瘤,0.048,0.0134,0.0791,0.0178,0.1359,0.0311,0.2501,0.0568,0.1839,0.0726,0.2911,0.0579,0.293,29.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为29.3%。
168,疾病_高血压 → 疾病_混合痔 → 药物_裸花紫珠分散片,-0.1787,-0.256,-0.1106,0.0391,-0.0073,-0.0982,0.0792,0.0472,-0.186,-0.2926,-0.0683,0.0596,1.0459,104.6,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为104.6%。
169,疾病_高血压 → 疾病_混合痔 → 药物_头孢地尼分散片,-0.1019,-0.1481,-0.0534,0.0259,0.002,-0.1053,0.1087,0.0577,-0.0999,-0.2116,0.0086,0.0595,1.4742,147.4,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为147.4%。
170,疾病_高血压 → 疾病_混合痔 → 疾病_肛乳头肥大,-0.1592,-0.2196,-0.092,0.0345,0.0166,-0.0802,0.1035,0.0497,-0.1426,-0.2408,-0.0303,0.0573,1.3798,138.0,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为138.0%。
171,疾病_高血压 → 检验_嗜酸性粒细胞数量 → 检验_嗜酸性粒细胞比率,-0.0192,-0.0813,0.0408,0.0325,-0.0497,-0.1399,0.0425,0.0487,-0.0689,-0.1733,0.0415,0.0591,3.3185,331.8,直接影响,强,负向中介,负向直接效应,完全中介,0.727,否,0.273,0.727,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为331.8%。
172,疾病_高血压 → 检验_嗜酸性粒细胞数量 → 疾病_心功能,-0.0061,-0.0246,0.0151,0.0109,0.0918,-0.0207,0.2003,0.0595,0.0857,-0.0241,0.1957,0.0603,-0.16,-16.0,直接影响,强,负向中介,正向直接效应,弱中介,0.724,否,0.276,0.724,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-16.0%。
173,疾病_高血压 → 疾病_非毒性多个甲状腺结节 → 疾病_血糖控制不佳,0.0349,-0.0019,0.0777,0.0217,-0.0146,-0.1149,0.087,0.0548,0.0203,-0.0922,0.1209,0.0584,-0.9469,-94.7,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9595,是,0.9595,0.0405,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-94.7%。
174,疾病_高血压 → 疾病_非毒性多个甲状腺结节 → 疾病_脂肪肝,0.027,-0.0055,0.0582,0.0177,0.1872,0.0888,0.2883,0.054,0.2143,0.111,0.3173,0.0562,0.1309,13.1,直接影响,强,正向中介,正向直接效应,弱中介,0.9545,是,0.9545,0.0455,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为13.1%。
175,疾病_高血压 → 疾病_非毒性多个甲状腺结节 → 检验_红细胞压积,-0.0269,-0.0573,0.0028,0.0167,-0.0195,-0.1257,0.0879,0.057,-0.0464,-0.1525,0.0669,0.0589,-1.8272,-182.7,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.959,是,0.041,0.959,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-182.7%。
176,疾病_高血压 → 疾病_非毒性多个甲状腺结节 → 疾病_老年性白内障,0.0167,-0.0031,0.0398,0.0118,0.1186,0.0063,0.2215,0.0575,0.1353,0.026,0.2414,0.0581,0.1538,15.4,直接影响,强,正向中介,正向直接效应,弱中介,0.954,是,0.954,0.046,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为15.4%。
177,疾病_高血压 → 疾病_非毒性多个甲状腺结节 → 疾病_后天性肾囊肿,0.0214,-0.0031,0.0497,0.0142,0.0869,-0.0222,0.197,0.0585,0.1083,-0.0073,0.2161,0.0597,0.1511,15.1,直接影响,强,正向中介,正向直接效应,弱中介,0.9515,是,0.9515,0.0485,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为15.1%。
178,疾病_高血压 → 检验_红细胞压积 → 检验_红细胞分布宽度CV,-0.0183,-0.0581,0.0207,0.0215,0.074,-0.0284,0.1643,0.052,0.0556,-0.0517,0.1607,0.0566,-0.4415,-44.2,直接影响,强,负向中介,正向直接效应,部分中介,0.809,否,0.191,0.809,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-44.2%。
179,疾病_高血压 → 检验_红细胞压积 → 检验_红细胞,-0.0245,-0.0769,0.0273,0.0286,0.015,-0.0827,0.1089,0.0517,-0.0096,-0.1208,0.0952,0.0588,3.4244,342.4,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.8095,否,0.1905,0.8095,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为342.4%。
180,疾病_高血压 → 检验_红细胞压积 → 检验_直接胆红素,-0.0029,-0.0139,0.006,0.0055,-0.172,-0.2831,-0.0644,0.0576,-0.1749,-0.2793,-0.0598,0.0578,0.018,1.8,直接影响,强,负向中介,负向直接效应,弱中介,0.703,否,0.297,0.703,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为1.8%。
181,疾病_高血压 → 检验_红细胞压积 → 药物_碳酸氢钠片,-0.0072,-0.0262,0.0106,0.0098,0.1145,0.0077,0.2221,0.0576,0.1073,0.0019,0.2166,0.058,-0.1078,-10.8,直接影响,强,负向中介,正向直接效应,弱中介,0.7835,否,0.2165,0.7835,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-10.8%。
182,疾病_高血压 → 药物_贞芪扶正 → 疾病_肺恶性肿瘤,-0.0199,-0.0513,0.0121,0.0172,0.2043,0.0954,0.3056,0.0561,0.1845,0.0782,0.2967,0.0583,-0.1396,-14.0,直接影响,强,负向中介,正向直接效应,弱中介,0.8875,否,0.1125,0.8875,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-14.0%。
183,疾病_高血压 → 药物_贞芪扶正 → 疾病_恶性肿瘤维持性化学治疗,-0.0196,-0.0514,0.0116,0.017,0.0535,-0.0553,0.1614,0.0575,0.0338,-0.0797,0.1428,0.0593,-0.4407,-44.1,直接影响,强,负向中介,正向直接效应,部分中介,0.887,否,0.113,0.887,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-44.1%。
184,疾病_高血压 → 检验_谷丙转氨酶 → 检验_谷草转氨酶,0.0165,-0.0219,0.0527,0.0201,0.022,-0.0775,0.1296,0.0555,0.0385,-0.068,0.1504,0.0585,0.0081,0.8,直接影响,强,正向中介,正向直接效应,弱中介,0.798,否,0.798,0.202,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为0.8%。
185,疾病_高血压 → 检验_谷丙转氨酶 → 检验_谷草/谷丙,0.0122,-0.0139,0.0416,0.0152,-0.099,-0.2085,0.0096,0.0577,-0.0868,-0.1892,0.0303,0.0591,-0.2367,-23.7,直接影响,强,正向中介,负向直接效应,部分中介,0.7855,否,0.7855,0.2145,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-23.7%。
186,疾病_高血压 → 检验_谷丙转氨酶 → 疾病_肺恶性肿瘤,0.0064,-0.0102,0.0243,0.0092,0.177,0.0685,0.2815,0.0575,0.1834,0.0697,0.2862,0.0578,0.0348,3.5,直接影响,强,正向中介,正向直接效应,弱中介,0.7755,否,0.7755,0.2245,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为3.5%。
187,疾病_高血压 → 疾病_前列腺增生 → 检验_钙,0.0204,-0.0,0.0427,0.012,0.1881,0.0801,0.2932,0.0581,0.2085,0.0992,0.3123,0.0576,0.1083,10.8,直接影响,强,正向中介,正向直接效应,弱中介,0.986,是,0.986,0.014,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为10.8%。
188,疾病_高血压 → 疾病_陈旧性脑梗死 → 药物_硫酸氢氯吡格雷片,0.1218,0.0649,0.1841,0.0321,0.0891,0.0083,0.1909,0.049,0.2109,0.1091,0.3105,0.0552,0.6041,60.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为60.4%。
189,疾病_高血压 → 疾病_陈旧性脑梗死 → 疾病_重度骨质疏松,0.0654,0.0292,0.1042,0.02,0.0642,-0.0425,0.1664,0.0561,0.1296,0.0217,0.2349,0.0568,0.4983,49.8,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为49.8%。
190,疾病_高血压 → 检验_血小板比容 → 检验_血小板,-0.0705,-0.1123,-0.0308,0.0219,0.0192,-0.0798,0.1301,0.0555,-0.0513,-0.1664,0.0539,0.0581,6.8463,684.6,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为684.6%。
191,疾病_高血压 → 疾病_肝囊肿 → 疾病_结肠息肉,0.0203,-0.0056,0.0492,0.0148,-0.0784,-0.185,0.0304,0.0587,-0.0581,-0.167,0.0545,0.06,-2.3787,-237.9,直接影响,强,正向中介,负向直接效应,完全中介,0.9245,否,0.9245,0.0755,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-237.9%。
192,疾病_高脂血症 → 疾病_动脉硬化 → 疾病_慢性胃炎,0.0678,0.026,0.1169,0.0247,0.0315,-0.0873,0.1458,0.0622,0.0993,-0.0105,0.208,0.0592,13.121,1312.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为1312.1%。
193,疾病_高脂血症 → 药物_匹伐他汀钙片 → 疾病_脂肪肝,0.0827,0.0405,0.1255,0.023,0.1618,0.0552,0.2676,0.0567,0.2445,0.1474,0.3492,0.0544,0.3607,36.1,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为36.1%。
194,疾病_高脂血症 → 药物_匹伐他汀钙片 → 药物_阿托伐他汀钙片,-0.0804,-0.1224,-0.0383,0.0223,0.3671,0.2589,0.4762,0.0572,0.2866,0.1827,0.3927,0.0566,-0.296,-29.6,直接影响,强,负向中介,正向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-29.6%。
195,疾病_高脂血症 → 药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片,0.0692,0.0299,0.108,0.0213,0.1151,0.009,0.2291,0.0596,0.1843,0.0801,0.296,0.0582,0.4296,43.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为43.0%。
196,疾病_高脂血症 → 药物_阿托伐他汀钙片 → 疾病_心律失常,-0.02,-0.056,0.0126,0.0179,0.0582,-0.0605,0.1675,0.0614,0.0382,-0.0739,0.1445,0.0584,-0.5174,-51.7,直接影响,强,负向中介,正向直接效应,部分中介,0.8765,否,0.1235,0.8765,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-51.7%。
197,疾病_高脂血症 → 疾病_腔隙性脑梗死 → 药物_劳拉西泮片,0.0459,0.0162,0.0784,0.0172,0.0875,-0.0208,0.1942,0.0577,0.1334,0.0199,0.2332,0.0574,0.2816,28.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为28.2%。
198,疾病_高脂血症 → 疾病_腔隙性脑梗死 → 疾病_高尿酸血症,-0.0109,-0.0354,0.0106,0.0125,0.1415,0.0225,0.2519,0.0605,0.1306,0.0146,0.2394,0.0598,-0.1346,-13.5,直接影响,强,负向中介,正向直接效应,弱中介,0.8225,否,0.1775,0.8225,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-13.5%。
199,疾病_高脂血症 → 疾病_前列腺增生 → 检验_钙,0.031,0.0032,0.0557,0.0142,-0.0349,-0.1443,0.0775,0.0596,-0.0039,-0.1157,0.1021,0.0594,0.1033,10.3,直接影响,强,正向中介,负向直接效应,弱中介,0.998,是,0.998,0.002,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为10.3%。
200,检验_血红蛋白 → 检验_红细胞分布宽度CV → 检验_钾,0.1304,0.0779,0.1963,0.032,0.0215,-0.0857,0.1418,0.0616,0.1519,0.0535,0.2628,0.0558,0.614,61.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为61.4%。
201,检验_血红蛋白 → 检验_红细胞分布宽度CV → 检验_红细胞分布宽度SD,0.2835,0.2098,0.3474,0.0381,0.067,-0.0322,0.1561,0.05,0.3504,0.251,0.4532,0.0542,0.8217,82.2,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为82.2%。
202,检验_血红蛋白 → 检验_红细胞分布宽度CV → 疾病_胆囊结石,0.0954,0.041,0.1568,0.0306,0.0024,-0.1161,0.1276,0.0654,0.0978,-0.0037,0.2145,0.0591,1.1131,111.3,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为111.3%。
203,检验_血红蛋白 → 检验_红细胞分布宽度CV → 检验_血小板,0.0511,-0.0003,0.108,0.0292,0.1059,-0.0219,0.2287,0.0667,0.1571,0.042,0.2679,0.0602,0.4014,40.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9635,是,0.9635,0.0365,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为40.1%。
204,检验_血红蛋白 → 检验_红细胞分布宽度CV → 检验_磷,0.0715,0.014,0.1272,0.0302,0.0295,-0.0933,0.1413,0.064,0.101,-0.0079,0.2074,0.0579,0.4546,45.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.994,是,0.994,0.006,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为45.5%。
205,检验_血红蛋白 → 检验_红细胞分布宽度CV → 检验_镁,0.0951,0.0347,0.1489,0.0296,0.1137,-0.0059,0.23,0.0634,0.2089,0.1007,0.3128,0.057,0.5024,50.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为50.2%。
206,检验_血红蛋白 → 检验_红细胞分布宽度CV → 检验_谷草/谷丙,0.0854,0.0363,0.1476,0.0293,0.1353,0.0164,0.2533,0.0626,0.2207,0.1199,0.3302,0.0559,0.4182,41.8,直接影响,强,正向中介,正向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为41.8%。
207,检验_血红蛋白 → 检验_红细胞压积 → 检验_红细胞分布宽度CV,0.097,0.0203,0.1764,0.0418,0.353,0.2289,0.4755,0.0657,0.45,0.3514,0.5402,0.051,0.2183,21.8,直接影响,强,正向中介,正向直接效应,部分中介,0.9905,是,0.9905,0.0095,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为21.8%。
208,检验_血红蛋白 → 检验_红细胞压积 → 检验_红细胞,0.1012,0.0369,0.164,0.0346,0.5501,0.4424,0.6465,0.0546,0.6513,0.5761,0.7411,0.0438,0.156,15.6,直接影响,强,正向中介,正向直接效应,弱中介,0.9965,是,0.9965,0.0035,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为15.6%。
209,检验_血红蛋白 → 检验_红细胞压积 → 检验_直接胆红素,-0.047,-0.1323,0.0342,0.0453,0.2355,0.097,0.3689,0.0714,0.1886,0.0839,0.294,0.0562,-0.3067,-30.7,直接影响,强,负向中介,正向直接效应,部分中介,0.8685,否,0.1315,0.8685,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-30.7%。
210,检验_血红蛋白 → 检验_红细胞压积 → 药物_碳酸氢钠片,0.1076,0.0235,0.1891,0.0453,-0.048,-0.1916,0.0857,0.0727,0.0596,-0.055,0.1647,0.0581,0.5761,57.6,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.9915,是,0.9915,0.0085,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为57.6%。
211,检验_血红蛋白 → 检验_红细胞 → 疾病_贫血,0.1159,0.017,0.2089,0.051,0.0677,-0.0829,0.1988,0.0763,0.1836,0.0806,0.2947,0.0573,0.7488,74.9,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.989,是,0.989,0.011,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为74.9%。
212,检验_血红蛋白 → 检验_红细胞 → 检验_白蛋白,0.1443,0.0546,0.2373,0.0487,0.1385,0.0066,0.2884,0.0749,0.2828,0.183,0.3842,0.0546,0.5354,53.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为53.5%。
213,检验_血红蛋白 → 检验_红细胞 → 疾病_白内障,0.0993,0.0053,0.1966,0.0494,-0.1559,-0.2937,-0.0108,0.0752,-0.0567,-0.1615,0.0518,0.0566,0.5778,57.8,直接影响,强,正向中介,负向直接效应,部分中介,0.9755,是,0.9755,0.0245,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为57.8%。
214,检验_血红蛋白 → 疾病_低蛋白血症 → 检验_白球比,0.1535,0.0985,0.2131,0.0309,0.1434,0.0397,0.2341,0.0514,0.2969,0.1937,0.4011,0.0549,0.5285,52.9,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为52.9%。
215,检验_血红蛋白 → 疾病_低蛋白血症 → 疾病_泌尿系感染,0.1221,0.0715,0.1743,0.0282,-0.033,-0.138,0.0722,0.0567,0.0891,-0.0166,0.2011,0.0584,-1.5238,-152.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-152.4%。
216,检验_血红蛋白 → 疾病_低蛋白血症 → 检验_C反应蛋白,0.1243,0.0758,0.176,0.0276,0.0967,-0.003,0.2023,0.0557,0.221,0.1235,0.3325,0.0564,0.6008,60.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为60.1%。
217,检验_血红蛋白 → 检验_胆碱酯酶 → 检验_前白蛋白,0.1727,0.1118,0.2349,0.0331,0.0471,-0.0508,0.1493,0.053,0.2199,0.1102,0.3179,0.0555,0.833,83.3,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为83.3%。
218,检验_碱性磷酸酶 → 检验_转肽酶 → 疾病_恶性肿瘤维持性化学治疗,0.1023,0.0436,0.163,0.0319,0.2153,0.0973,0.3286,0.0616,0.3176,0.2172,0.4218,0.0549,0.3314,33.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为33.1%。
219,检验_碱性磷酸酶 → 检验_转肽酶 → 药物_骨化三醇胶丸,0.0006,-0.0565,0.0612,0.0314,-0.0466,-0.1599,0.0872,0.0668,-0.0461,-0.1565,0.0632,0.0589,0.0715,7.2,直接影响,强,正向中介,负向直接效应,弱中介,0.5135,否,0.5135,0.4865,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为7.2%。
220,检验_碱性磷酸酶 → 检验_转肽酶 → 疾病_非毒性单个甲状腺结节,0.1111,0.0488,0.177,0.0343,-0.1763,-0.3007,-0.0544,0.0654,-0.0652,-0.1707,0.0474,0.058,-1.6554,-165.5,直接影响,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-165.5%。
221,检验_碱性磷酸酶 → 药物_盐酸吗啡注射液 → 药物_盐酸布桂嗪注射液,0.0439,0.0083,0.0791,0.0192,0.1843,0.0793,0.3,0.0592,0.2283,0.1236,0.3375,0.0575,0.1056,10.6,直接影响,强,正向中介,正向直接效应,弱中介,0.9935,是,0.9935,0.0065,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为10.6%。
222,检验_碱性磷酸酶 → 药物_盐酸羟考酮缓释片 → 药物_盐酸布桂嗪注射液,0.2117,0.1471,0.2804,0.0354,0.015,-0.0891,0.1319,0.0582,0.2268,0.1162,0.332,0.058,0.9966,99.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为99.7%。
223,检验_碱性磷酸酶 → 药物_盐酸羟考酮缓释片 → 药物_硝苯地平缓释片,0.1811,0.1181,0.2389,0.0324,0.0573,-0.0522,0.1604,0.0569,0.2384,0.1384,0.35,0.0557,0.8002,80.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为80.0%。
224,检验_碱性磷酸酶 → 检验_尿酸 → 疾病_高尿酸血症,0.0647,0.0273,0.103,0.021,-0.2012,-0.3081,-0.0918,0.0595,-0.1365,-0.2444,-0.0304,0.0589,-0.5983,-59.8,直接影响,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-59.8%。
225,检验_碱性磷酸酶 → 检验_尿酸 → 疾病_重度骨质疏松,0.0081,-0.0184,0.0371,0.0147,-0.0621,-0.1626,0.0618,0.0589,-0.054,-0.1558,0.0575,0.0569,-0.2178,-21.8,直接影响,强,正向中介,负向直接效应,部分中介,0.7035,否,0.7035,0.2965,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-21.8%。
226,检验_碱性磷酸酶 → 检验_尿酸 → 检验_钾,0.0403,0.0102,0.0726,0.0169,-0.0119,-0.1194,0.1082,0.0603,0.0284,-0.0791,0.1366,0.0583,0.2668,26.7,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为26.7%。
227,检验_碱性磷酸酶 → 检验_尿酸 → 疾病_慢性胃炎,-0.0288,-0.0569,-0.0009,0.0152,0.0506,-0.0565,0.1694,0.0604,0.0218,-0.0795,0.1396,0.0599,-0.7761,-77.6,直接影响,强,负向中介,正向直接效应,部分中介,0.9855,是,0.0145,0.9855,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-77.6%。
228,检验_碱性磷酸酶 → 检验_尿酸 → 药物_劳拉西泮片,0.0146,-0.0115,0.0444,0.0146,-0.0688,-0.1984,0.0419,0.0626,-0.0542,-0.164,0.0632,0.0603,-0.0373,-3.7,直接影响,强,正向中介,负向直接效应,弱中介,0.8705,否,0.8705,0.1295,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-3.7%。
229,药物_肝素钠注射液 → 疾病_脑梗死 → 疾病_糖尿病性视网膜病变,0.0336,-0.0416,0.1005,0.0375,-0.0604,-0.1849,0.0691,0.0689,-0.0268,-0.1378,0.0766,0.0578,-2.8744,-287.4,直接影响,强,正向中介,负向直接效应,完全中介,0.825,否,0.825,0.175,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-287.4%。
230,药物_肝素钠注射液 → 药物_氯化钠注射液 → 药物_葡萄糖注射液,0.1764,0.1165,0.2426,0.0333,0.3649,0.267,0.4751,0.0548,0.5412,0.4548,0.6296,0.0477,0.3278,32.8,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为32.8%。
231,检验_前白蛋白 → 检验_镁 → 检验_碳酸氢盐,0.0618,0.0244,0.1086,0.0225,0.1206,0.0078,0.2325,0.0605,0.1824,0.0767,0.2889,0.0574,0.3813,38.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.1%。
232,检验_前白蛋白 → 检验_总胆红素 → 检验_直接胆红素,0.1879,0.1312,0.2504,0.0332,0.0922,-0.0135,0.1862,0.0523,0.2801,0.1728,0.3787,0.0546,0.6903,69.0,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为69.0%。
233,检验_前白蛋白 → 检验_总胆红素 → 检验_间接胆红素,0.2974,0.2055,0.3771,0.046,-0.0303,-0.0957,0.0442,0.0372,0.2671,0.1642,0.3658,0.0544,1.1373,113.7,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为113.7%。
234,检验_前白蛋白 → 检验_总胆红素 → 疾病_非毒性单个甲状腺结节,0.087,0.0409,0.1348,0.0253,-0.1275,-0.2352,-0.0188,0.0584,-0.0405,-0.1454,0.0612,0.0565,1.7909,179.1,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为179.1%。
235,检验_红细胞平均体积 → 检验_平均血红蛋白含量 → 疾病_贫血,0.0672,0.0111,0.1308,0.032,0.0685,-0.0508,0.1929,0.0643,0.1357,0.0304,0.2445,0.0569,0.6236,62.4,直接影响,强,正向中介,正向直接效应,部分中介,0.983,是,0.983,0.017,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为62.4%。
236,检验_红细胞平均体积 → 检验_平均血红蛋白含量 → 疾病_类风湿性关节炎,0.0639,0.0053,0.1227,0.0311,-0.1254,-0.2425,0.0148,0.0674,-0.0615,-0.1801,0.0454,0.0599,-0.5518,-55.2,直接影响,强,正向中介,负向直接效应,部分中介,0.982,是,0.982,0.018,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-55.2%。
237,疾病_反流性食管炎 → 药物_贞芪扶正 → 疾病_肺恶性肿瘤,0.0995,0.0546,0.1505,0.026,-0.0755,-0.1899,0.0387,0.0614,0.024,-0.0893,0.1334,0.059,3.577,357.7,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为357.7%。
238,疾病_反流性食管炎 → 药物_贞芪扶正 → 疾病_恶性肿瘤维持性化学治疗,0.0658,0.0242,0.1037,0.0215,0.26,0.1491,0.3646,0.0575,0.3257,0.2306,0.4355,0.0546,0.2074,20.7,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为20.7%。
239,疾病_反流性食管炎 → 疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸,0.0562,0.0176,0.0995,0.0217,0.0728,-0.0375,0.194,0.062,0.129,0.0329,0.2495,0.0584,0.5814,58.1,直接影响,强,正向中介,正向直接效应,部分中介,0.997,是,0.997,0.003,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为58.1%。
240,疾病_反流性食管炎 → 疾病_胆囊结石 → 疾病_脂肪肝,-0.0062,-0.0417,0.0306,0.0189,-0.0867,-0.1948,0.0209,0.0571,-0.0929,-0.2066,0.0206,0.0601,0.1321,13.2,直接影响,强,负向中介,负向直接效应,弱中介,0.6305,否,0.3695,0.6305,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为13.2%。
241,疾病_反流性食管炎 → 疾病_胆囊结石 → 检验_钙,0.0005,-0.0059,0.0089,0.0037,0.0836,-0.0251,0.1949,0.06,0.0841,-0.0259,0.1929,0.0602,-0.0522,-5.2,直接影响,强,正向中介,正向直接效应,弱中介,0.5295,否,0.5295,0.4705,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-5.2%。
242,疾病_反流性食管炎 → 疾病_胆囊结石 → 药物_盐酸二甲双胍片,-0.0048,-0.0357,0.025,0.0165,-0.144,-0.2471,-0.0382,0.0559,-0.1488,-0.2534,-0.0385,0.0575,0.1879,18.8,直接影响,强,负向中介,负向直接效应,弱中介,0.6135,否,0.3865,0.6135,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为18.8%。
243,疾病_反流性食管炎 → 疾病_胆囊结石 → 药物_甲钴胺片,-0.0029,-0.0209,0.016,0.0099,0.0714,-0.042,0.1771,0.0588,0.0686,-0.048,0.1734,0.0597,-0.0345,-3.5,直接影响,强,负向中介,正向直接效应,弱中介,0.622,否,0.378,0.622,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-3.5%。
244,疾病_反流性食管炎 → 疾病_贫血 → 药物_琥珀酸亚铁片,0.0591,0.0264,0.0996,0.02,-0.0977,-0.2147,0.0024,0.0572,-0.0387,-0.1482,0.0642,0.0573,-5.3294,-532.9,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-532.9%。
245,疾病_反流性食管炎 → 疾病_混合痔 → 药物_裸花紫珠分散片,-0.1264,-0.2013,-0.0604,0.0374,-0.0112,-0.0974,0.0704,0.0449,-0.1376,-0.2536,-0.0365,0.0573,1.0555,105.5,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为105.5%。
246,疾病_反流性食管炎 → 疾病_混合痔 → 药物_头孢地尼分散片,-0.0709,-0.1146,-0.03,0.0228,-0.0008,-0.1035,0.1064,0.0562,-0.0718,-0.1788,0.0405,0.0586,-6.166,-616.6,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-616.6%。
247,疾病_反流性食管炎 → 疾病_混合痔 → 疾病_肛乳头肥大,-0.1103,-0.1706,-0.0461,0.0336,-0.0027,-0.0872,0.0941,0.0496,-0.113,-0.2176,-0.0093,0.0567,1.4249,142.5,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为142.5%。
248,疾病_反流性食管炎 → 疾病_糖尿病性周围神经病 → 疾病_糖尿病性周围血管病,-0.0309,-0.0801,0.0254,0.0284,-0.043,-0.1301,0.0564,0.0509,-0.0739,-0.1802,0.0355,0.058,0.5,50.0,直接影响,强,负向中介,负向直接效应,部分中介,0.8605,否,0.1395,0.8605,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为50.0%。
249,疾病_反流性食管炎 → 疾病_糖尿病性周围神经病 → 疾病_糖尿病性视网膜病变,-0.0232,-0.0601,0.0144,0.0207,-0.0721,-0.1801,0.0226,0.0541,-0.0953,-0.1956,0.0183,0.0581,0.0938,9.4,直接影响,强,负向中介,负向直接效应,弱中介,0.8735,否,0.1265,0.8735,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为9.4%。
250,疾病_反流性食管炎 → 疾病_糖尿病性周围神经病 → 疾病_高尿酸血症,-0.022,-0.0573,0.0112,0.0191,-0.1311,-0.2361,-0.0252,0.055,-0.1531,-0.2567,-0.0409,0.058,0.1732,17.3,直接影响,强,负向中介,负向直接效应,弱中介,0.8785,否,0.1215,0.8785,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为17.3%。
251,疾病_反流性食管炎 → 疾病_糖尿病性周围神经病 → 药物_甲钴胺片,-0.017,-0.0475,0.0105,0.0158,0.0869,-0.0171,0.1882,0.0558,0.0699,-0.0413,0.1766,0.058,-0.0191,-1.9,直接影响,强,负向中介,正向直接效应,弱中介,0.8675,否,0.1325,0.8675,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-1.9%。
252,疾病_反流性食管炎 → 药物_琥珀酸亚铁片 → 药物_叶酸片,-0.0173,-0.0604,0.0283,0.0243,0.0356,-0.0656,0.1361,0.0541,0.0183,-0.0872,0.133,0.0595,-2.4628,-246.3,直接影响,强,负向中介,正向直接效应,完全中介,0.7575,否,0.2425,0.7575,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-246.3%。
253,疾病_反流性食管炎 → 药物_琥珀酸亚铁片 → 疾病_糖尿病性周围血管病,-0.0107,-0.0412,0.0172,0.0158,-0.0642,-0.1787,0.0307,0.0567,-0.0749,-0.1897,0.027,0.0589,0.0712,7.1,直接影响,强,负向中介,负向直接效应,弱中介,0.7465,否,0.2535,0.7465,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为7.1%。
254,检验_淋巴细胞比率 → 检验_中性粒细胞比率 → 检验_中性粒细胞数量,0.2986,0.2074,0.396,0.0501,0.0769,-0.0502,0.2,0.0672,0.3755,0.282,0.4819,0.0524,0.8091,80.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为80.9%。
255,检验_淋巴细胞比率 → 检验_淋巴细胞数量 → 检验_直接胆红素,0.1009,0.0439,0.1569,0.0301,0.0967,-0.0233,0.2131,0.0631,0.1976,0.0898,0.3025,0.0567,0.5714,57.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为57.1%。
256,检验_淋巴细胞比率 → 检验_淋巴细胞数量 → 检验_碳酸氢盐,0.0178,-0.0389,0.0653,0.028,0.0822,-0.0409,0.2083,0.0652,0.1,-0.0065,0.2061,0.0581,0.0924,9.2,直接影响,强,正向中介,正向直接效应,弱中介,0.7415,否,0.7415,0.2585,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为9.2%。
257,检验_嗜酸性粒细胞比率 → 检验_嗜酸性粒细胞数量 → 疾病_心功能,0.0752,-0.0086,0.1451,0.0411,0.0944,-0.0381,0.2251,0.0706,0.1696,0.0589,0.27,0.0568,0.5314,53.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9645,是,0.9645,0.0355,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为53.1%。
258,检验_嗜酸性粒细胞比率 → 药物_硝苯地平控释片 → 药物_厄贝沙坦片,-0.0281,-0.0652,0.0049,0.0187,0.1111,0.0067,0.2179,0.0571,0.083,-0.04,0.185,0.0597,-0.1247,-12.5,直接影响,强,负向中介,正向直接效应,弱中介,0.9515,是,0.0485,0.9515,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-12.5%。
259,检验_嗜酸性粒细胞比率 → 药物_硝苯地平控释片 → 药物_厄贝沙坦氢氯噻嗪片,-0.0277,-0.0632,0.0038,0.0183,-0.0345,-0.1387,0.07,0.0564,-0.0622,-0.1669,0.0524,0.0587,0.658,65.8,直接影响,强,负向中介,负向直接效应,部分中介,0.9505,是,0.0495,0.9505,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为65.8%。
260,检验_嗜酸性粒细胞比率 → 疾病_医疗机构新收治患者及陪护人员 → 疾病_慢性胃炎,0.0075,-0.0213,0.0351,0.015,-0.1103,-0.2184,-0.0076,0.0559,-0.1028,-0.2088,0.0067,0.0576,0.4755,47.6,直接影响,强,正向中介,负向直接效应,部分中介,0.6915,否,0.6915,0.3085,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为47.6%。
261,药物_匹伐他汀钙片 → 疾病_脂肪肝 → 疾病_胆囊结石,0.0847,0.0447,0.1287,0.0229,0.2158,0.1137,0.3312,0.0583,0.3006,0.1976,0.4052,0.0562,0.2911,29.1,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为29.1%。
262,药物_匹伐他汀钙片 → 疾病_脂肪肝 → 检验_C反应蛋白,-0.0552,-0.0952,-0.0171,0.0213,-0.1041,-0.2186,0.0126,0.063,-0.1594,-0.2648,-0.0374,0.0599,0.3812,38.1,直接影响,强,负向中介,负向直接效应,部分中介,0.9955,是,0.0045,0.9955,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.1%。
263,药物_匹伐他汀钙片 → 疾病_脂肪肝 → 疾病_糖尿病性周围血管病,0.0537,0.0171,0.09,0.0196,0.3282,0.2147,0.4288,0.0577,0.3818,0.2785,0.4801,0.0545,0.1436,14.4,直接影响,强,正向中介,正向直接效应,弱中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为14.4%。
264,药物_匹伐他汀钙片 → 疾病_脂肪肝 → 疾病_肺恶性肿瘤,0.0987,0.0557,0.1491,0.0253,-0.1887,-0.3023,-0.0858,0.0575,-0.09,-0.2005,0.0076,0.0558,-2.8772,-287.7,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-287.7%。
265,药物_匹伐他汀钙片 → 药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片,-0.0391,-0.0729,-0.009,0.0176,0.0283,-0.0829,0.1309,0.0583,-0.0108,-0.1189,0.1025,0.0601,-1.2058,-120.6,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.991,是,0.009,0.991,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-120.6%。
266,药物_匹伐他汀钙片 → 药物_阿托伐他汀钙片 → 疾病_心律失常,0.0064,-0.0097,0.0249,0.0092,0.039,-0.0767,0.1541,0.0626,0.0454,-0.0724,0.1591,0.0628,-0.2136,-21.4,直接影响,强,正向中介,正向直接效应,部分中介,0.78,否,0.78,0.22,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-21.4%。
267,药物_氯化钾注射液 → 疾病_肺部感染 → 疾病_低钾血症,0.1787,0.1,0.2692,0.0438,0.112,-0.0165,0.2445,0.0682,0.2907,0.1897,0.4032,0.0565,0.6392,63.9,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为63.9%。
268,药物_氯化钾注射液 → 疾病_肺部感染 → 药物_葡萄糖注射液,0.0572,-0.0079,0.1145,0.0324,0.6353,0.5433,0.7379,0.0527,0.6926,0.6169,0.7714,0.0407,0.083,8.3,直接影响,强,正向中介,正向直接效应,弱中介,0.958,是,0.958,0.042,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为8.3%。
269,药物_氯化钾注射液 → 疾病_肺部感染 → 检验_血小板,0.127,0.0413,0.2106,0.0451,-0.0675,-0.1971,0.0716,0.0719,0.0595,-0.0436,0.1775,0.059,8.9529,895.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为895.3%。
270,药物_氯化钾注射液 → 疾病_肺部感染 → 检验_镁,-0.0092,-0.0942,0.0708,0.0439,0.1482,0.0269,0.2958,0.0716,0.1391,0.03,0.2412,0.0563,-0.0744,-7.4,直接影响,强,负向中介,正向直接效应,弱中介,0.582,否,0.418,0.582,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-7.4%。
271,药物_氯化钾注射液 → 药物_维生素C注射液 → 药物_维生素B6注射液,0.4314,0.3532,0.5057,0.042,0.1644,0.0896,0.2509,0.0419,0.5958,0.515,0.687,0.0464,0.7255,72.6,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为72.6%。
272,药物_氯化钾注射液 → 药物_氯化钠注射液 → 药物_葡萄糖注射液,0.1083,0.053,0.1687,0.0311,0.5843,0.4899,0.6818,0.0504,0.6927,0.6107,0.7642,0.041,0.1568,15.7,直接影响,强,正向中介,正向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为15.7%。
273,药物_氯化钾注射液 → 检验_平均血红蛋白浓度 → 药物_复方鲜竹沥液,0.0318,0.0002,0.0644,0.0174,0.3263,0.2278,0.4387,0.0565,0.3581,0.2564,0.456,0.054,0.091,9.1,直接影响,强,正向中介,正向直接效应,弱中介,0.9755,是,0.9755,0.0245,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为9.1%。
274,药物_氯化钾注射液 → 检验_平均血红蛋白浓度 → 药物_佐匹克隆片,0.0705,0.0302,0.1123,0.022,-0.0922,-0.214,0.0126,0.0603,-0.0216,-0.13,0.0861,0.0586,1.5682,156.8,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为156.8%。
275,药物_氯化钾注射液 → 药物_盐酸氨溴索注射液 → 药物_二羟丙茶碱注射液,0.8435,0.6758,0.9948,0.0854,0.005,-0.1579,0.1701,0.0871,0.8485,0.7898,0.9042,0.0302,0.995,99.5,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为99.5%。
276,药物_氯化钾注射液 → 药物_盐酸氨溴索注射液 → 检验_碳酸氢盐,0.3197,-0.0018,0.6382,0.1724,-0.0866,-0.4246,0.2622,0.1805,0.233,0.1231,0.3375,0.0573,1.4815,148.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9695,是,0.9695,0.0305,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为148.1%。
277,药物_氯化钾注射液 → 药物_盐酸氨溴索注射液 → 药物_肝素钠注射液,0.7934,0.6057,0.9851,0.1006,0.005,-0.1772,0.2154,0.1048,0.7983,0.7329,0.866,0.0352,0.9954,99.5,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为99.5%。
278,疾病_高同型半胱氨酸血症 → 药物_叶酸片 → 药物_卡维地洛片,0.151,0.0955,0.2071,0.0304,0.2239,0.1185,0.3237,0.055,0.3749,0.2752,0.472,0.0525,0.4088,40.9,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为40.9%。
279,疾病_高同型半胱氨酸血症 → 药物_叶酸片 → 药物_甲钴胺分散片,0.1209,0.0691,0.1803,0.03,0.1084,-0.0017,0.2185,0.0594,0.2292,0.124,0.3276,0.0552,0.5604,56.0,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为56.0%。
280,疾病_高同型半胱氨酸血症 → 药物_叶酸片 → 药物_琥珀酸亚铁片,0.2323,0.1677,0.3027,0.0363,-0.27,-0.3773,-0.1618,0.0569,-0.0377,-0.1406,0.0796,0.0581,-1.6067,-160.7,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-160.7%。
281,疾病_高同型半胱氨酸血症 → 疾病_肢体动脉硬化 → 疾病_颈总动脉斑块,0.1123,0.0617,0.1662,0.0288,0.0128,-0.0924,0.1088,0.0542,0.125,0.0192,0.2283,0.0576,1.0635,106.4,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为106.4%。
282,疾病_高同型半胱氨酸血症 → 疾病_肢体动脉硬化 → 药物_艾司唑仑片,0.0695,0.0324,0.1094,0.0207,-0.1147,-0.2187,0.0048,0.0591,-0.0452,-0.1539,0.0642,0.059,1.5923,159.2,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为159.2%。
283,检验_大型血小板比率 → 检验_血小板分布宽度 → 检验_平均血小板体积,0.2689,0.1973,0.3442,0.0395,0.1132,0.011,0.2273,0.0571,0.3821,0.2813,0.4775,0.0531,0.7141,71.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为71.4%。
284,检验_大型血小板比率 → 检验_血小板分布宽度 → 检验_中性粒细胞数量,0.0903,0.0188,0.1535,0.0363,0.0249,-0.0971,0.1558,0.0681,0.1153,-0.0066,0.2194,0.0602,-0.2223,-22.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.9935,是,0.9935,0.0065,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-22.2%。
285,检验_大型血小板比率 → 疾病_医疗机构新收治患者及陪护人员 → 疾病_慢性胃炎,0.0514,0.0198,0.0885,0.0185,-0.0936,-0.2043,0.0117,0.0583,-0.0422,-0.156,0.0592,0.0589,0.2551,25.5,直接影响,强,正向中介,负向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为25.5%。
286,检验_大型血小板比率 → 疾病_老年性白内障 → 疾病_白内障,0.1233,0.0726,0.1776,0.0284,0.0321,-0.0782,0.1407,0.0593,0.1555,0.0458,0.2519,0.0559,0.9788,97.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为97.9%。
287,检验_血小板分布宽度 → 检验_大型血小板比率 → 疾病_医疗机构新收治患者及陪护人员,0.1191,0.0492,0.1844,0.0365,-0.0807,-0.2128,0.046,0.069,0.0384,-0.0754,0.1457,0.0595,-6.613,-661.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-661.3%。
288,检验_血小板分布宽度 → 检验_大型血小板比率 → 疾病_老年性白内障,0.1984,0.1322,0.2744,0.0377,-0.0108,-0.128,0.1138,0.0635,0.1876,0.0859,0.2875,0.054,1.1825,118.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为118.2%。
289,检验_血小板分布宽度 → 检验_中性粒细胞数量 → 检验_白细胞,0.0939,0.0377,0.1455,0.0294,0.0755,-0.0191,0.1738,0.0518,0.1694,0.0678,0.2786,0.0572,0.613,61.3,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为61.3%。
290,检验_血小板分布宽度 → 检验_中性粒细胞数量 → 检验_单核细胞数量,0.0604,0.0243,0.1013,0.0209,0.0271,-0.0776,0.1362,0.0576,0.0875,-0.0204,0.1969,0.0593,0.9787,97.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为97.9%。
291,检验_血小板分布宽度 → 检验_中性粒细胞数量 → 检验_镁,0.032,0.0074,0.06,0.0145,-0.1115,-0.2277,-0.0009,0.0597,-0.0796,-0.1948,0.0267,0.059,0.0825,8.3,直接影响,强,正向中介,负向直接效应,弱中介,0.999,是,0.999,0.001,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为8.3%。
292,检验_血小板分布宽度 → 检验_中性粒细胞数量 → 药物_复方鲜竹沥液,0.0143,-0.0058,0.0407,0.0122,0.0121,-0.1037,0.1261,0.061,0.0264,-0.0868,0.1391,0.0598,-0.1953,-19.5,间接影响（中介效应）,强,正向中介,正向直接效应,弱中介,0.9,否,0.9,0.1,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-19.5%。
293,检验_血小板分布宽度 → 检验_中性粒细胞数量 → 药物_苯磺酸氨氯地平片,-0.0235,-0.049,-0.0009,0.0132,-0.0113,-0.1261,0.1074,0.0611,-0.0348,-0.1445,0.0845,0.0604,-1.8532,-185.3,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.9825,是,0.0175,0.9825,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-185.3%。
294,检验_直接胆红素 → 检验_总胆汁酸 → 检验_转肽酶,0.0642,0.0295,0.1052,0.0204,0.218,0.1117,0.3226,0.0572,0.2822,0.1818,0.3829,0.0553,0.2362,23.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为23.6%。
295,检验_直接胆红素 → 检验_碱性磷酸酶 → 检验_转肽酶,0.1413,0.0934,0.1991,0.0285,0.1424,0.0427,0.2468,0.0551,0.2837,0.1793,0.3912,0.0586,0.5154,51.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为51.5%。
296,检验_直接胆红素 → 检验_碱性磷酸酶 → 药物_盐酸吗啡注射液,0.0801,0.0386,0.1223,0.0229,0.119,0.0109,0.2293,0.0599,0.1991,0.0833,0.3007,0.0581,0.4446,44.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为44.5%。
297,检验_直接胆红素 → 检验_碱性磷酸酶 → 药物_盐酸羟考酮缓释片,0.117,0.0688,0.165,0.0263,0.2301,0.1093,0.3191,0.0551,0.347,0.2415,0.4448,0.0543,0.3433,34.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为34.3%。
298,检验_直接胆红素 → 检验_碱性磷酸酶 → 检验_尿酸,0.0673,0.0282,0.1106,0.0225,0.0947,-0.0246,0.2018,0.061,0.162,0.0523,0.2649,0.0582,0.4758,47.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为47.6%。
299,检验_直接胆红素 → 检验_碱性磷酸酶 → 疾病_肝功能异常,0.0769,0.0372,0.121,0.0229,0.021,-0.0842,0.1374,0.0598,0.0979,-0.0057,0.1993,0.0572,0.5365,53.6,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为53.6%。
300,检验_直接胆红素 → 药物_盐酸羟考酮缓释片 → 药物_盐酸布桂嗪注射液,0.1666,0.1104,0.2255,0.0317,0.0289,-0.0751,0.1332,0.0555,0.1955,0.0893,0.2981,0.0567,0.8166,81.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为81.7%。
301,检验_直接胆红素 → 药物_盐酸羟考酮缓释片 → 药物_硝苯地平缓释片,0.1563,0.1021,0.2149,0.0304,-0.0211,-0.1274,0.0843,0.0559,0.1352,0.0294,0.2461,0.0579,0.549,54.9,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为54.9%。
302,检验_直接胆红素 → 药物_盐酸羟考酮缓释片 → 检验_碱性磷酸酶,0.1273,0.0804,0.1818,0.0277,0.1967,0.0989,0.3042,0.0554,0.324,0.2211,0.4258,0.0551,0.4016,40.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为40.2%。
303,检验_直接胆红素 → 检验_总胆红素 → 检验_间接胆红素,0.4134,0.337,0.4987,0.0423,0.1005,0.0262,0.1796,0.0409,0.5138,0.4251,0.6084,0.0488,0.8071,80.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为80.7%。
304,检验_直接胆红素 → 检验_总胆红素 → 疾病_非毒性单个甲状腺结节,0.135,0.0582,0.2075,0.0398,-0.0896,-0.2135,0.0343,0.0661,0.0454,-0.0581,0.1576,0.058,-2.4723,-247.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-247.2%。
305,检验_谷丙转氨酶 → 检验_谷草转氨酶 → 疾病_腰椎间盘突出,-0.0439,-0.0861,-0.0031,0.0222,-0.0638,-0.1722,0.0559,0.0604,-0.1078,-0.2239,-0.0067,0.0574,0.7404,74.0,直接影响,强,负向中介,负向直接效应,部分中介,0.9785,是,0.0215,0.9785,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为74.0%。
306,检验_谷丙转氨酶 → 疾病_肺恶性肿瘤 → 疾病_前列腺增生,0.0165,-0.0005,0.0384,0.011,-0.0454,-0.1577,0.0638,0.059,-0.029,-0.1421,0.0764,0.0588,-0.1909,-19.1,直接影响,强,正向中介,负向直接效应,弱中介,0.9735,是,0.9735,0.0265,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-19.1%。
307,检验_谷丙转氨酶 → 疾病_肺恶性肿瘤 → 疾病_恶性肿瘤维持性化学治疗,0.0422,0.0099,0.0778,0.0184,0.0035,-0.1032,0.1061,0.057,0.0457,-0.0546,0.1532,0.058,0.5911,59.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.9975,是,0.9975,0.0025,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为59.1%。
308,检验_谷丙转氨酶 → 疾病_肺恶性肿瘤 → 检验_单核细胞数量,0.0053,-0.0121,0.0227,0.0089,0.0126,-0.0989,0.1169,0.0585,0.0179,-0.0903,0.1216,0.058,0.0866,8.7,直接影响,强,正向中介,正向直接效应,弱中介,0.7455,否,0.7455,0.2545,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为8.7%。
309,检验_红细胞分布宽度CV → 检验_红细胞分布宽度SD → 检验_红细胞,0.1832,0.0927,0.2722,0.0485,0.1952,0.0642,0.334,0.0712,0.3784,0.2867,0.4785,0.0519,0.494,49.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为49.4%。
310,检验_红细胞分布宽度CV → 检验_红细胞分布宽度SD → 检验_红细胞平均体积,0.0772,-0.0161,0.1776,0.0519,0.1329,-0.0156,0.276,0.0775,0.2102,0.1085,0.3149,0.0549,0.4182,41.8,直接影响,强,正向中介,正向直接效应,部分中介,0.9325,否,0.9325,0.0675,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为41.8%。
311,检验_红细胞分布宽度CV → 疾病_胆囊结石 → 疾病_脂肪肝,0.0756,0.0339,0.1193,0.0236,-0.0966,-0.1996,0.0036,0.0564,-0.021,-0.1278,0.0845,0.0583,0.1847,18.5,直接影响,强,正向中介,负向直接效应,弱中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为18.5%。
312,检验_红细胞分布宽度CV → 疾病_胆囊结石 → 检验_钙,-0.0121,-0.0358,0.0121,0.0129,0.1355,0.0359,0.2554,0.0584,0.1233,0.0155,0.2274,0.0567,-0.0857,-8.6,直接影响,强,负向中介,正向直接效应,弱中介,0.8415,否,0.1585,0.8415,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-8.6%。
313,检验_红细胞分布宽度CV → 疾病_胆囊结石 → 药物_盐酸二甲双胍片,0.0605,0.0248,0.0976,0.0199,0.0363,-0.0702,0.1549,0.0585,0.0968,-0.0078,0.2128,0.0585,-23.0104,-2301.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-2301.0%。
314,检验_红细胞分布宽度CV → 疾病_胆囊结石 → 药物_甲钴胺片,0.0359,0.0069,0.0642,0.016,-0.0403,-0.1499,0.073,0.0595,-0.0044,-0.114,0.1011,0.0585,-0.0815,-8.2,直接影响,强,正向中介,负向直接效应,弱中介,0.998,是,0.998,0.002,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-8.2%。
315,检验_红细胞分布宽度CV → 检验_血小板 → 药物_维生素C注射液,0.0264,0.0047,0.0535,0.0136,0.1882,0.0815,0.2981,0.0572,0.2145,0.1095,0.3206,0.0567,0.1322,13.2,直接影响,强,正向中介,正向直接效应,弱中介,0.9955,是,0.9955,0.0045,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为13.2%。
316,检验_红细胞分布宽度CV → 检验_血小板 → 检验_血小板比容,0.0573,0.0156,0.0974,0.0223,-0.0312,-0.1424,0.0676,0.0552,0.0261,-0.0792,0.1282,0.0576,-0.3004,-30.0,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-30.0%。
317,检验_红细胞分布宽度CV → 检验_磷 → 药物_碳酸钙片,0.0284,0.0045,0.0548,0.0141,0.018,-0.1073,0.1181,0.0599,0.0464,-0.0734,0.1473,0.06,0.1103,11.0,间接影响（中介效应）,强,正向中介,正向直接效应,弱中介,0.9975,是,0.9975,0.0025,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为弱中介，中介比例为11.0%。
318,检验_红细胞分布宽度CV → 检验_镁 → 检验_碳酸氢盐,0.0514,0.0204,0.086,0.0181,0.0885,-0.0319,0.1962,0.06,0.1399,0.0208,0.239,0.0575,0.4947,49.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为49.5%。
319,药物_盐酸氨溴索注射液 → 药物_二羟丙茶碱注射液 → 药物_阿卡波糖片,0.3685,0.16,0.5813,0.1124,-0.0688,-0.3075,0.1618,0.1241,0.2998,0.2019,0.4093,0.0544,1.274,127.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为127.4%。
320,药物_盐酸氨溴索注射液 → 药物_二羟丙茶碱注射液 → 药物_富马酸比索洛尔片,0.2174,-0.0132,0.4167,0.1131,-0.0669,-0.2879,0.1874,0.1263,0.1505,0.0412,0.268,0.0597,1.5894,158.9,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9695,是,0.9695,0.0305,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为158.9%。
321,药物_盐酸氨溴索注射液 → 药物_二羟丙茶碱注射液 → 药物_酒石酸美托洛尔片,0.3038,0.0818,0.4938,0.1085,-0.0458,-0.2657,0.18,0.1204,0.258,0.1587,0.3628,0.0551,1.2387,123.9,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.996,是,0.996,0.004,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为123.9%。
322,药物_盐酸氨溴索注射液 → 药物_二羟丙茶碱注射液 → 药物_维生素C注射液,-0.7531,-0.9205,-0.5753,0.0914,1.2543,1.0714,1.4508,0.1011,0.5012,0.4112,0.5905,0.0485,-1.5181,-151.8,直接影响,强,负向中介,正向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-151.8%。
323,药物_盐酸氨溴索注射液 → 药物_肝素钠注射液 → 疾病_脑梗死,0.478,0.3243,0.6294,0.0812,-0.0451,-0.2273,0.1278,0.0936,0.4329,0.3312,0.5276,0.052,1.1195,112.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为112.0%。
324,药物_盐酸氨溴索注射液 → 药物_肝素钠注射液 → 药物_氯化钠注射液,0.1706,0.0248,0.3055,0.0741,0.386,0.2215,0.5574,0.089,0.5566,0.4727,0.6518,0.0473,0.309,30.9,直接影响,强,正向中介,正向直接效应,部分中介,0.9885,是,0.9885,0.0115,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为30.9%。
325,检验_转肽酶 → 疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸,0.0549,0.0141,0.0935,0.0212,0.0766,-0.0377,0.1916,0.0614,0.1315,0.0218,0.2414,0.0593,0.5649,56.5,直接影响,强,正向中介,正向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为56.5%。
326,检验_转肽酶 → 检验_碱性磷酸酶 → 药物_盐酸吗啡注射液,0.1152,0.0569,0.179,0.0328,0.0917,-0.0296,0.2133,0.0652,0.2069,0.098,0.3074,0.0571,0.6341,63.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为63.4%。
327,检验_转肽酶 → 检验_碱性磷酸酶 → 药物_盐酸羟考酮缓释片,0.1797,0.1141,0.2396,0.0343,0.1323,0.0242,0.2407,0.0581,0.3121,0.2093,0.412,0.0544,0.5914,59.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为59.1%。
328,检验_转肽酶 → 检验_碱性磷酸酶 → 检验_尿酸,0.1091,0.052,0.1727,0.0326,0.0199,-0.1014,0.1412,0.0638,0.129,0.0099,0.2245,0.0579,1.2847,128.5,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为128.5%。
329,检验_转肽酶 → 检验_碱性磷酸酶 → 疾病_肝功能异常,0.1121,0.0567,0.1784,0.0324,0.0294,-0.0889,0.143,0.0626,0.1415,0.0309,0.2377,0.0561,1.0156,101.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为101.6%。
330,检验_转肽酶 → 药物_骨化三醇胶丸 → 疾病_类风湿性关节炎,-0.0085,-0.051,0.0317,0.0222,-0.054,-0.1639,0.0457,0.056,-0.0625,-0.1778,0.0498,0.06,0.1777,17.8,直接影响,强,负向中介,负向直接效应,弱中介,0.643,否,0.357,0.643,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为17.8%。
331,检验_转肽酶 → 药物_骨化三醇胶丸 → 药物_碳酸钙片,-0.0086,-0.0529,0.0366,0.0238,0.0725,-0.0211,0.171,0.0531,0.0639,-0.0438,0.1696,0.0581,0.2031,20.3,直接影响,强,负向中介,正向直接效应,部分中介,0.6455,否,0.3545,0.6455,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为20.3%。
332,检验_转肽酶 → 药物_骨化三醇胶丸 → 药物_酒石酸美托洛尔片,-0.0058,-0.0388,0.0265,0.0171,0.0261,-0.0762,0.1324,0.0565,0.0204,-0.094,0.1232,0.0589,-0.0614,-6.1,直接影响,强,负向中介,正向直接效应,弱中介,0.64,否,0.36,0.64,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-6.1%。
333,药物_二羟丙茶碱注射液 → 药物_阿卡波糖片 → 疾病_非毒性单个甲状腺结节,0.1259,0.0755,0.1863,0.0299,-0.1564,-0.2629,-0.0392,0.0598,-0.0305,-0.1467,0.0706,0.0581,9.7874,978.7,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为978.7%。
334,药物_二羟丙茶碱注射液 → 药物_阿卡波糖片 → 药物_精蛋白生物合成人胰岛素注射液,0.0874,0.0399,0.1346,0.0253,-0.1086,-0.2243,-0.0029,0.0592,-0.0212,-0.1307,0.0824,0.0558,0.1306,13.1,直接影响,强,正向中介,负向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为13.1%。
335,药物_二羟丙茶碱注射液 → 药物_阿卡波糖片 → 检验_谷草转氨酶,0.0556,0.014,0.1005,0.0239,0.0847,-0.0377,0.1931,0.0622,0.1403,0.0341,0.2512,0.057,0.3818,38.2,直接影响,强,正向中介,正向直接效应,部分中介,0.992,是,0.992,0.008,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.2%。
336,药物_二羟丙茶碱注射液 → 药物_阿卡波糖片 → 疾病_糖尿病性周围神经病,0.1652,0.1083,0.2275,0.032,-0.2297,-0.3345,-0.1195,0.0566,-0.0645,-0.1726,0.0459,0.0587,-9.4879,-948.8,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-948.8%。
337,药物_二羟丙茶碱注射液 → 药物_阿卡波糖片 → 疾病_泌尿系感染,0.0763,0.0351,0.1233,0.0235,0.1796,0.0659,0.2954,0.0612,0.2559,0.1529,0.3693,0.0578,0.315,31.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为31.5%。
338,药物_二羟丙茶碱注射液 → 药物_富马酸比索洛尔片 → 药物_硝苯地平缓释片,0.043,0.0133,0.0731,0.0163,0.1255,0.016,0.2342,0.0592,0.1686,0.062,0.2826,0.0589,0.2967,29.7,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为29.7%。
339,药物_二羟丙茶碱注射液 → 药物_富马酸比索洛尔片 → 疾病_心律失常,0.0325,0.0065,0.0616,0.0147,-0.0158,-0.1206,0.0976,0.0584,0.0167,-0.0926,0.1243,0.0586,-0.2053,-20.5,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.997,是,0.997,0.003,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-20.5%。
340,药物_二羟丙茶碱注射液 → 药物_富马酸比索洛尔片 → 药物_甲钴胺片,0.0129,-0.0074,0.0372,0.0119,-0.0561,-0.1606,0.0644,0.0594,-0.0432,-0.1511,0.0645,0.0582,-0.0797,-8.0,直接影响,强,正向中介,负向直接效应,弱中介,0.885,否,0.885,0.115,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-8.0%。
341,药物_二羟丙茶碱注射液 → 药物_酒石酸美托洛尔片 → 药物_富马酸比索洛尔片,-0.0481,-0.0834,-0.0118,0.0194,0.2288,0.1151,0.3515,0.0624,0.1807,0.0699,0.299,0.0603,-0.3133,-31.3,直接影响,强,负向中介,正向直接效应,部分中介,0.998,是,0.002,0.998,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-31.3%。
342,药物_二羟丙茶碱注射液 → 药物_酒石酸美托洛尔片 → 药物_硝苯地平缓释片,0.0351,0.0014,0.0742,0.0193,0.1339,0.0139,0.2367,0.0603,0.169,0.0631,0.2785,0.0584,0.2525,25.3,直接影响,强,正向中介,正向直接效应,部分中介,0.9755,是,0.9755,0.0245,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为25.3%。
343,药物_二羟丙茶碱注射液 → 药物_维生素C注射液 → 药物_维生素B6注射液,0.225,0.1414,0.3055,0.0456,-0.0641,-0.1303,0.0022,0.0351,0.1608,0.0536,0.253,0.0553,1.5427,154.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为154.3%。
344,检验_总蛋白 → 检验_钙 → 检验_嗜碱性粒细胞比率,-0.0231,-0.0603,0.0095,0.0181,0.0181,-0.1013,0.1353,0.0624,-0.005,-0.1174,0.1073,0.059,-0.1096,-11.0,间接影响（中介效应）,强,负向中介,正向直接效应,弱中介,0.914,否,0.086,0.914,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-11.0%。
345,检验_总蛋白 → 检验_球蛋白 → 疾病_结肠息肉,0.0444,0.0074,0.0823,0.0199,-0.0809,-0.1912,0.0366,0.0611,-0.0365,-0.1522,0.0679,0.0592,1.9166,191.7,直接影响,强,正向中介,负向直接效应,完全中介,0.9905,是,0.9905,0.0095,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为191.7%。
346,疾病_动脉硬化 → 疾病_慢性胃炎 → 疾病_结肠息肉,0.0472,0.0171,0.0798,0.0175,0.0724,-0.0347,0.183,0.0574,0.1195,0.0035,0.2186,0.0569,0.3295,32.9,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为32.9%。
347,疾病_动脉硬化 → 疾病_高脂血症 → 药物_匹伐他汀钙片,0.1007,0.0538,0.1483,0.0262,0.0949,-0.0103,0.2082,0.0577,0.1957,0.097,0.2999,0.0557,0.5675,56.8,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为56.8%。
348,疾病_动脉硬化 → 疾病_高脂血症 → 药物_阿托伐他汀钙片,0.082,0.0401,0.1319,0.025,0.166,0.0651,0.2866,0.0591,0.248,0.1458,0.3544,0.0566,0.3485,34.8,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为34.8%。
349,疾病_动脉硬化 → 疾病_高脂血症 → 疾病_腔隙性脑梗死,0.052,0.0091,0.0956,0.0234,0.1436,0.0335,0.2622,0.0612,0.1956,0.0907,0.3084,0.0582,0.3128,31.3,直接影响,强,正向中介,正向直接效应,部分中介,0.995,是,0.995,0.005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为31.3%。
350,疾病_动脉硬化 → 疾病_高脂血症 → 疾病_前列腺增生,0.0559,0.0125,0.1004,0.0238,0.0206,-0.1011,0.1323,0.0628,0.0765,-0.039,0.175,0.0581,-4.1783,-417.8,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.996,是,0.996,0.004,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-417.8%。
351,检验_总胆红素 → 检验_直接胆红素 → 检验_总胆汁酸,0.1399,0.0665,0.2122,0.0388,0.0714,-0.0528,0.2015,0.0679,0.2112,0.1053,0.3202,0.0577,0.7306,73.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为73.1%。
352,检验_总胆红素 → 检验_直接胆红素 → 检验_碱性磷酸酶,0.1758,0.099,0.2449,0.039,0.0053,-0.1239,0.1299,0.067,0.1811,0.067,0.2804,0.0579,1.1115,111.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为111.1%。
353,检验_总胆红素 → 检验_直接胆红素 → 药物_盐酸羟考酮缓释片,0.1526,0.0803,0.2245,0.0381,0.1272,0.004,0.2428,0.064,0.2798,0.1738,0.3807,0.0544,0.5666,56.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为56.7%。
354,检验_总胆红素 → 检验_直接胆红素 → 疾病_泌尿系感染,-0.0504,-0.1162,0.0279,0.0381,-0.0317,-0.1594,0.1048,0.07,-0.082,-0.1902,0.0264,0.0578,0.1536,15.4,间接影响（中介效应）,强,负向中介,负向直接效应,弱中介,0.9025,否,0.0975,0.9025,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为15.4%。
355,疾病_尿毒症 → 检验_胆碱酯酶 → 检验_前白蛋白,0.3267,0.2422,0.4059,0.0439,-0.367,-0.4701,-0.2693,0.0533,-0.0402,-0.1471,0.0742,0.0584,28.5998,2860.0,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为2860.0%。
356,疾病_尿毒症 → 检验_谷丙转氨酶 → 检验_谷草转氨酶,0.1123,0.0526,0.1659,0.0303,0.2056,0.089,0.3175,0.0614,0.3178,0.2113,0.4175,0.0558,0.3637,36.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为36.4%。
357,疾病_尿毒症 → 检验_谷丙转氨酶 → 检验_谷草/谷丙,0.1166,0.0582,0.1767,0.0318,-0.0146,-0.132,0.0987,0.0621,0.102,-0.0064,0.2122,0.0571,1.3907,139.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为139.1%。
358,疾病_尿毒症 → 检验_谷丙转氨酶 → 疾病_肺恶性肿瘤,0.0934,0.0365,0.1528,0.0309,-0.1449,-0.2632,-0.0231,0.0635,-0.0515,-0.1522,0.0619,0.0583,-1.1407,-114.1,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-114.1%。
359,疾病_尿毒症 → 疾病_高血压 → 药物_阿司匹林肠溶片,-0.0693,-0.1104,-0.0336,0.0211,-0.029,-0.1274,0.0796,0.0571,-0.0983,-0.2106,0.008,0.0583,1.2277,122.8,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为122.8%。
360,疾病_尿毒症 → 疾病_高血压 → 药物_富马酸比索洛尔片,-0.0559,-0.0913,-0.0199,0.0197,-0.0166,-0.1215,0.1008,0.0589,-0.0725,-0.1904,0.0317,0.0589,0.8598,86.0,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为86.0%。
361,疾病_尿毒症 → 疾病_高血压 → 药物_硝苯地平控释片,-0.0529,-0.0866,-0.0182,0.0188,-0.0054,-0.1135,0.1108,0.0591,-0.0584,-0.1705,0.0529,0.0592,0.7395,73.9,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为73.9%。
362,疾病_尿毒症 → 疾病_高血压 → 疾病_肝功能异常,-0.0354,-0.0648,-0.0041,0.0166,-0.0135,-0.1232,0.093,0.0587,-0.0489,-0.1583,0.0546,0.0581,1.2134,121.3,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.9945,是,0.0055,0.9945,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为121.3%。
363,疾病_尿毒症 → 疾病_高血压 → 药物_厄贝沙坦氢氯噻嗪片,-0.0405,-0.0723,-0.0087,0.0169,-0.0006,-0.1133,0.1112,0.0606,-0.0412,-0.1511,0.072,0.0595,1.7228,172.3,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为172.3%。
364,疾病_尿毒症 → 疾病_高血压 → 疾病_糖尿病,-0.0585,-0.094,-0.0236,0.0193,-0.124,-0.2242,-0.0103,0.0572,-0.1824,-0.2944,-0.0783,0.0573,0.3949,39.5,直接影响,强,负向中介,负向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为39.5%。
365,疾病_尿毒症 → 疾病_高血压 → 疾病_反流性食管炎,-0.0014,-0.0281,0.0255,0.0143,-0.1055,-0.2212,0.0051,0.0611,-0.1069,-0.2206,0.0012,0.06,-0.0106,-1.1,直接影响,强,负向中介,负向直接效应,弱中介,0.543,否,0.457,0.543,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-1.1%。
366,疾病_尿毒症 → 疾病_高血压 → 疾病_动脉硬化,-0.0338,-0.0658,-0.0043,0.0164,-0.0604,-0.1789,0.05,0.0617,-0.0942,-0.2034,0.0245,0.061,0.576,57.6,直接影响,强,负向中介,负向直接效应,部分中介,0.989,是,0.011,0.989,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为57.6%。
367,疾病_尿毒症 → 疾病_高血压 → 疾病_脂肪肝,-0.0481,-0.0808,-0.0149,0.018,-0.0436,-0.1515,0.0704,0.0587,-0.0917,-0.2013,0.0159,0.058,0.5956,59.6,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,0.999,是,0.001,0.999,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为59.6%。
368,疾病_尿毒症 → 疾病_高血压 → 疾病_混合痔,0.0724,0.0349,0.1104,0.021,-0.1345,-0.2359,-0.0227,0.058,-0.0621,-0.1755,0.0426,0.0593,-2.3905,-239.0,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-239.0%。
369,疾病_尿毒症 → 疾病_高血压 → 检验_嗜酸性粒细胞数量,0.013,-0.0149,0.0402,0.015,-0.0806,-0.198,0.0268,0.0611,-0.0676,-0.17,0.0516,0.0601,-0.4389,-43.9,直接影响,强,正向中介,负向直接效应,部分中介,0.8175,否,0.8175,0.1825,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-43.9%。
370,疾病_尿毒症 → 疾病_高血压 → 疾病_非毒性多个甲状腺结节,-0.0198,-0.0476,0.0072,0.0148,-0.045,-0.1621,0.0668,0.062,-0.0649,-0.1727,0.0488,0.0606,-0.2607,-26.1,直接影响,强,负向中介,负向直接效应,部分中介,0.919,否,0.081,0.919,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-26.1%。
371,疾病_尿毒症 → 疾病_高血压 → 检验_红细胞压积,0.0032,-0.0246,0.0297,0.0142,0.1482,0.0332,0.2506,0.0579,0.1514,0.045,0.2567,0.0568,0.0374,3.7,直接影响,强,正向中介,正向直接效应,弱中介,0.588,否,0.588,0.412,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为3.7%。
372,疾病_尿毒症 → 疾病_高血压 → 药物_贞芪扶正,0.0217,-0.0053,0.051,0.0152,-0.0799,-0.1996,0.0308,0.062,-0.0582,-0.1675,0.0606,0.0609,0.0823,8.2,直接影响,强,正向中介,负向直接效应,弱中介,0.9415,否,0.9415,0.0585,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为8.2%。
373,疾病_尿毒症 → 疾病_高血压 → 检验_谷丙转氨酶,-0.0392,-0.0696,-0.0125,0.0159,0.486,0.3874,0.5787,0.0522,0.4468,0.3484,0.5397,0.0517,-0.0895,-8.9,直接影响,强,负向中介,正向直接效应,弱中介,0.998,是,0.002,0.998,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-8.9%。
374,疾病_尿毒症 → 疾病_高血压 → 药物_盐酸二甲双胍片,-0.0437,-0.0776,-0.0138,0.0175,-0.0119,-0.1207,0.1038,0.0598,-0.0556,-0.161,0.058,0.0586,3.5219,352.2,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.9985,是,0.0015,0.9985,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为352.2%。
375,疾病_尿毒症 → 疾病_高血压 → 疾病_前列腺增生,-0.0271,-0.0564,0.0004,0.0153,-0.0384,-0.1557,0.0691,0.061,-0.0655,-0.1731,0.0465,0.0598,-0.4228,-42.3,直接影响,强,负向中介,负向直接效应,部分中介,0.9745,是,0.0255,0.9745,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-42.3%。
376,疾病_尿毒症 → 疾病_高血压 → 疾病_陈旧性脑梗死,-0.0542,-0.0883,-0.0195,0.0189,0.0006,-0.1074,0.1167,0.0591,-0.0536,-0.1658,0.0574,0.0592,0.1933,19.3,间接影响（中介效应）,强,负向中介,正向直接效应,弱中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为弱中介，中介比例为19.3%。
377,疾病_尿毒症 → 疾病_高血压 → 检验_血小板比容,0.052,0.0218,0.0871,0.0179,-0.0791,-0.1929,0.0327,0.0608,-0.0272,-0.1401,0.0894,0.0609,-0.4644,-46.4,直接影响,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-46.4%。
378,疾病_尿毒症 → 疾病_高血压 → 药物_苯磺酸氨氯地平片,-0.0569,-0.0929,-0.0208,0.0197,-0.0007,-0.1079,0.1131,0.0585,-0.0577,-0.1689,0.0523,0.059,0.857,85.7,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为85.7%。
379,疾病_尿毒症 → 疾病_高血压 → 疾病_肝囊肿,-0.018,-0.0472,0.0079,0.0148,-0.0249,-0.1445,0.0848,0.0624,-0.0428,-0.1509,0.0742,0.061,-2.4576,-245.8,直接影响,强,负向中介,负向直接效应,完全中介,0.9025,否,0.0975,0.9025,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-245.8%。
380,疾病_尿毒症 → 检验_淋巴细胞数量 → 检验_淋巴细胞比率,0.1502,0.0955,0.205,0.0299,0.0921,-0.0134,0.2,0.0577,0.2423,0.1394,0.3602,0.0577,0.6535,65.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为65.4%。
381,疾病_尿毒症 → 检验_淋巴细胞数量 → 检验_直接胆红素,0.0839,0.0384,0.1354,0.0258,0.1425,0.0301,0.2625,0.0615,0.2264,0.1135,0.3322,0.0584,0.3934,39.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为39.3%。
382,疾病_尿毒症 → 检验_淋巴细胞数量 → 检验_碳酸氢盐,0.0139,-0.031,0.0607,0.0235,0.1067,-0.0148,0.2243,0.0645,0.1205,0.0028,0.2242,0.0598,0.0314,3.1,直接影响,强,正向中介,正向直接效应,弱中介,0.725,否,0.725,0.275,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为3.1%。
383,疾病_尿毒症 → 检验_肌酐 → 疾病_腔隙性脑梗死,-0.0503,-0.0924,-0.0094,0.0223,-0.0094,-0.1255,0.1038,0.0603,-0.0597,-0.1673,0.046,0.0564,-0.2527,-25.3,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,0.9935,是,0.0065,0.9935,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-25.3%。
384,疾病_尿毒症 → 检验_红细胞平均体积 → 检验_平均血红蛋白含量,0.1718,0.1072,0.2281,0.0331,-0.1116,-0.2081,0.0011,0.056,0.0602,-0.0417,0.1708,0.0572,24.1047,2410.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为2410.5%。
385,疾病_肺部感染 → 疾病_低钾血症 → 疾病_心功能,0.083,0.0405,0.1356,0.025,-0.089,-0.2117,0.0166,0.0608,-0.0061,-0.1111,0.1016,0.0576,0.0455,4.6,直接影响,强,正向中介,负向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为4.6%。
386,疾病_肺部感染 → 疾病_低钾血症 → 检验_钾,0.1013,0.053,0.1536,0.0268,0.0813,-0.0301,0.1944,0.0602,0.1826,0.077,0.2901,0.0578,0.6144,61.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为61.4%。
387,疾病_肺部感染 → 检验_血小板 → 药物_维生素C注射液,0.0232,0.0028,0.0466,0.0123,0.3393,0.2304,0.4403,0.0566,0.3625,0.2506,0.4633,0.0562,0.0651,6.5,直接影响,强,正向中介,正向直接效应,弱中介,0.9935,是,0.9935,0.0065,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为6.5%。
388,疾病_肺部感染 → 检验_血小板 → 检验_血小板比容,0.0618,0.0182,0.104,0.023,-0.1105,-0.213,0.0007,0.0561,-0.0486,-0.1574,0.0616,0.0591,0.2487,24.9,直接影响,强,正向中介,负向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为24.9%。
389,疾病_肺部感染 → 检验_镁 → 检验_碳酸氢盐,0.016,-0.0069,0.0413,0.0134,0.0828,-0.0337,0.1846,0.0575,0.0988,-0.0162,0.2071,0.0588,0.2497,25.0,直接影响,强,正向中介,正向直接效应,部分中介,0.908,否,0.908,0.092,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为25.0%。
390,疾病_非毒性多个甲状腺结节 → 疾病_血糖控制不佳 → 药物_精蛋白生物合成人胰岛素注射液,0.0388,-0.0052,0.084,0.0237,-0.0019,-0.127,0.1106,0.0622,0.0369,-0.0734,0.142,0.0578,-0.2305,-23.1,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.9545,是,0.9545,0.0455,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-23.1%。
391,疾病_非毒性多个甲状腺结节 → 疾病_脂肪肝 → 疾病_胆囊结石,0.1017,0.0569,0.148,0.0255,0.0017,-0.1027,0.1108,0.0577,0.1034,0.0005,0.2122,0.0571,2.1554,215.5,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为215.5%。
392,疾病_非毒性多个甲状腺结节 → 疾病_脂肪肝 → 检验_C反应蛋白,-0.0612,-0.1048,-0.0263,0.0213,-0.0122,-0.1324,0.0929,0.0608,-0.0734,-0.186,0.0344,0.0595,-1.1501,-115.0,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-115.0%。
393,疾病_非毒性多个甲状腺结节 → 疾病_脂肪肝 → 疾病_糖尿病性周围血管病,0.0688,0.0306,0.1101,0.0215,0.1595,0.0542,0.2734,0.0594,0.2284,0.1248,0.3359,0.0577,0.3223,32.2,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为32.2%。
394,疾病_非毒性多个甲状腺结节 → 疾病_脂肪肝 → 疾病_肺恶性肿瘤,0.0697,0.0319,0.1142,0.0221,0.0824,-0.0293,0.1876,0.0585,0.1521,0.0487,0.2581,0.0566,0.5237,52.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为52.4%。
395,疾病_非毒性多个甲状腺结节 → 检验_红细胞压积 → 检验_红细胞分布宽度CV,-0.1009,-0.1492,-0.0561,0.0258,-0.0582,-0.1651,0.0434,0.0565,-0.1591,-0.2643,-0.0515,0.0578,0.697,69.7,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为69.7%。
396,疾病_非毒性多个甲状腺结节 → 检验_红细胞压积 → 检验_红细胞,-0.1413,-0.2018,-0.0893,0.0308,0.0148,-0.0876,0.1143,0.0531,-0.1265,-0.2369,-0.0214,0.0579,1.0976,109.8,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为109.8%。
397,疾病_非毒性多个甲状腺结节 → 检验_红细胞压积 → 检验_直接胆红素,-0.0177,-0.0499,0.0137,0.0169,-0.0276,-0.1454,0.087,0.0612,-0.0453,-0.1593,0.0629,0.0589,0.0283,2.8,直接影响,强,负向中介,负向直接效应,弱中介,0.862,否,0.138,0.862,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为2.8%。
398,疾病_非毒性多个甲状腺结节 → 检验_红细胞压积 → 药物_碳酸氢钠片,-0.0504,-0.0902,-0.018,0.0189,0.1245,0.0184,0.2423,0.0594,0.0741,-0.0364,0.1837,0.0581,-0.5352,-53.5,直接影响,强,负向中介,正向直接效应,部分中介,0.9985,是,0.0015,0.9985,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-53.5%。
399,疾病_非毒性多个甲状腺结节 → 疾病_老年性白内障 → 疾病_白内障,0.0581,0.0234,0.0991,0.0207,0.1369,0.0284,0.2348,0.0552,0.195,0.0856,0.3021,0.0577,0.3962,39.6,直接影响,强,正向中介,正向直接效应,部分中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为39.6%。
400,疾病_非毒性多个甲状腺结节 → 疾病_老年性白内障 → 检验_大型血小板比率,0.0746,0.0312,0.1219,0.0247,-0.0874,-0.1861,0.0176,0.0549,-0.0128,-0.1285,0.0836,0.0572,-1.073,-107.3,直接影响,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-107.3%。
401,药物_阿司匹林肠溶片 → 疾病_重度骨质疏松 → 药物_骨化三醇胶丸,-0.0655,-0.1269,-0.0055,0.0333,0.0245,-0.069,0.1158,0.0496,-0.041,-0.1537,0.0584,0.0577,1.1788,117.9,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.978,是,0.022,0.978,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为117.9%。
402,药物_阿司匹林肠溶片 → 疾病_重度骨质疏松 → 药物_碳酸钙片,-0.0453,-0.0886,0.0,0.0231,0.0503,-0.0557,0.1445,0.053,0.005,-0.1061,0.1064,0.0571,0.4858,48.6,直接影响,强,负向中介,正向直接效应,部分中介,0.976,是,0.024,0.976,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为48.6%。
403,药物_阿司匹林肠溶片 → 药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片,0.0758,0.0326,0.1203,0.0232,0.1367,0.025,0.2528,0.0598,0.2125,0.1079,0.3258,0.0578,0.3829,38.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.3%。
404,药物_阿司匹林肠溶片 → 药物_阿托伐他汀钙片 → 疾病_心律失常,-0.0199,-0.0603,0.017,0.0206,0.033,-0.0965,0.145,0.0637,0.0132,-0.0985,0.1242,0.0597,-0.1509,-15.1,直接影响,强,负向中介,正向直接效应,弱中介,0.8405,否,0.1595,0.8405,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-15.1%。
405,药物_骨化三醇胶丸 → 药物_碳酸钙片 → 疾病_糖尿病性视网膜病变,0.0746,0.0248,0.1266,0.0274,-0.0313,-0.1555,0.0812,0.0635,0.0433,-0.0722,0.1459,0.058,6.0504,605.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为605.0%。
406,药物_骨化三醇胶丸 → 药物_酒石酸美托洛尔片 → 药物_富马酸比索洛尔片,-0.0312,-0.066,0.0061,0.0192,0.0521,-0.0557,0.172,0.0616,0.021,-0.0878,0.1305,0.0592,-0.4397,-44.0,直接影响,强,负向中介,正向直接效应,部分中介,0.955,是,0.045,0.955,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-44.0%。
407,药物_骨化三醇胶丸 → 药物_酒石酸美托洛尔片 → 药物_硝苯地平缓释片,0.0481,0.0116,0.0842,0.0194,-0.0346,-0.1404,0.0781,0.0593,0.0135,-0.0865,0.1239,0.0571,0.4881,48.8,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.996,是,0.996,0.004,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为48.8%。
408,检验_尿酸 → 疾病_高尿酸血症 → 药物_碳酸氢钠片,0.0851,0.0411,0.1331,0.0246,0.0128,-0.1062,0.1164,0.0589,0.0979,-0.021,0.2049,0.061,0.7932,79.3,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为79.3%。
409,检验_尿酸 → 疾病_高尿酸血症 → 药物_硝苯地平控释片,0.0794,0.0372,0.1254,0.0238,-0.012,-0.1125,0.1008,0.0562,0.0674,-0.0398,0.1729,0.0576,1.5256,152.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为152.6%。
410,检验_尿酸 → 疾病_重度骨质疏松 → 药物_骨化三醇胶丸,0.0136,-0.0451,0.0761,0.0325,-0.0325,-0.1264,0.0596,0.0496,-0.0189,-0.1296,0.0897,0.0591,-0.2741,-27.4,直接影响,强,正向中介,负向直接效应,部分中介,0.6665,否,0.6665,0.3335,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-27.4%。
411,检验_尿酸 → 疾病_重度骨质疏松 → 药物_碳酸钙片,0.0094,-0.029,0.0503,0.0217,-0.0391,-0.1314,0.0663,0.0534,-0.0297,-0.1373,0.0799,0.0587,0.3588,35.9,直接影响,强,正向中介,负向直接效应,部分中介,0.66,否,0.66,0.34,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为35.9%。
412,检验_尿酸 → 疾病_慢性胃炎 → 疾病_结肠息肉,-0.0263,-0.0557,-0.0005,0.0152,-0.0833,-0.1859,0.0256,0.0562,-0.1096,-0.2208,-0.003,0.0574,-0.1393,-13.9,直接影响,强,负向中介,负向直接效应,弱中介,0.976,是,0.024,0.976,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-13.9%。
413,药物_贞芪扶正 → 疾病_肺恶性肿瘤 → 疾病_前列腺增生,0.0418,0.0096,0.0805,0.019,-0.1544,-0.2627,-0.022,0.0632,-0.1126,-0.2225,0.003,0.0603,-0.4164,-41.6,直接影响,强,正向中介,负向直接效应,部分中介,0.9945,是,0.9945,0.0055,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-41.6%。
414,药物_贞芪扶正 → 疾病_肺恶性肿瘤 → 疾病_恶性肿瘤维持性化学治疗,0.0649,0.0259,0.1029,0.0208,0.2165,0.1118,0.3269,0.0567,0.2814,0.1771,0.3854,0.0553,0.2392,23.9,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为23.9%。
415,药物_贞芪扶正 → 疾病_肺恶性肿瘤 → 检验_单核细胞数量,0.0139,-0.02,0.047,0.0175,-0.0401,-0.159,0.0653,0.061,-0.0262,-0.1413,0.0749,0.0581,0.0732,7.3,直接影响,强,正向中介,负向直接效应,弱中介,0.7995,否,0.7995,0.2005,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为7.3%。
416,药物_贞芪扶正 → 疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸,0.0614,0.0252,0.1036,0.0209,-0.0627,-0.174,0.0514,0.0607,-0.0013,-0.1017,0.1191,0.0581,-0.0943,-9.4,直接影响,强,正向中介,负向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-9.4%。
417,疾病_重度骨质疏松 → 药物_骨化三醇胶丸 → 疾病_类风湿性关节炎,0.1541,0.0814,0.2313,0.04,0.2181,0.0995,0.3409,0.0655,0.3722,0.2673,0.4724,0.0553,0.4227,42.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为42.3%。
418,疾病_重度骨质疏松 → 药物_骨化三醇胶丸 → 药物_碳酸钙片,0.161,0.0863,0.2299,0.0382,0.2289,0.1105,0.3406,0.0621,0.3898,0.2904,0.4821,0.0519,0.4197,42.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为42.0%。
419,疾病_重度骨质疏松 → 药物_骨化三醇胶丸 → 药物_酒石酸美托洛尔片,0.182,0.1035,0.2589,0.0417,-0.0476,-0.1813,0.0706,0.067,0.1344,0.0374,0.2426,0.0563,4.0703,407.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为407.0%。
420,疾病_重度骨质疏松 → 药物_碳酸钙片 → 药物_骨化三醇胶丸,0.0876,0.0453,0.134,0.0234,0.4823,0.389,0.5795,0.0512,0.5699,0.4753,0.6583,0.0479,0.1544,15.4,直接影响,强,正向中介,正向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为15.4%。
421,疾病_重度骨质疏松 → 药物_碳酸钙片 → 疾病_糖尿病性视网膜病变,0.0702,0.0243,0.1221,0.0261,-0.0344,-0.1619,0.0749,0.0634,0.0357,-0.0797,0.1399,0.0585,-1.0215,-102.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-102.2%。
422,检验_葡萄糖 → 疾病_肝囊肿 → 疾病_结肠息肉,-0.0538,-0.085,-0.0198,0.0178,-0.0082,-0.121,0.0993,0.0585,-0.0621,-0.1734,0.0507,0.0591,0.0343,3.4,间接影响（中介效应）,强,负向中介,负向直接效应,弱中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为弱中介，中介比例为3.4%。
423,检验_葡萄糖 → 疾病_糖尿病 → 疾病_糖尿病性周围神经病,0.158,0.0932,0.2155,0.0326,0.0519,-0.0687,0.1631,0.0614,0.2099,0.1098,0.3208,0.0568,0.8225,82.3,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为82.3%。
424,检验_葡萄糖 → 疾病_糖尿病 → 药物_甲钴胺分散片,0.1242,0.0622,0.1832,0.032,-0.0364,-0.157,0.0782,0.0631,0.0878,-0.0215,0.1947,0.0575,2.1576,215.8,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为215.8%。
425,检验_葡萄糖 → 疾病_糖尿病 → 药物_阿卡波糖片,0.159,0.1028,0.2223,0.0319,0.1557,0.0551,0.2771,0.0593,0.3147,0.2096,0.4177,0.0557,0.5197,52.0,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为52.0%。
426,检验_葡萄糖 → 疾病_糖尿病 → 药物_盐酸二甲双胍片,0.1592,0.0984,0.2221,0.0336,-0.086,-0.2116,0.0248,0.0625,0.0733,-0.0321,0.1843,0.0588,1.5063,150.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为150.6%。
427,检验_葡萄糖 → 疾病_糖尿病 → 检验_尿酸,0.0761,0.0186,0.1332,0.0309,-0.0075,-0.1249,0.1169,0.0646,0.0687,-0.0418,0.1846,0.0593,0.9283,92.8,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9915,是,0.9915,0.0085,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为92.8%。
428,检验_葡萄糖 → 疾病_糖尿病 → 疾病_肝囊肿,-0.0523,-0.1054,0.003,0.0288,-0.174,-0.294,-0.0571,0.0623,-0.2263,-0.3382,-0.1292,0.0557,0.2508,25.1,直接影响,强,负向中介,负向直接效应,部分中介,0.9675,是,0.0325,0.9675,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为25.1%。
429,检验_葡萄糖 → 药物_碳酸钙片 → 药物_骨化三醇胶丸,-0.0057,-0.0479,0.0383,0.0233,-0.0059,-0.1024,0.1002,0.0545,-0.0116,-0.1196,0.0959,0.0582,0.2312,23.1,直接影响,强,负向中介,负向直接效应,部分中介,0.6065,否,0.3935,0.6065,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为23.1%。
430,检验_葡萄糖 → 药物_碳酸钙片 → 疾病_糖尿病性视网膜病变,-0.0017,-0.0216,0.0171,0.0102,0.1279,0.0085,0.2294,0.0592,0.1263,0.0152,0.239,0.0599,-0.0256,-2.6,直接影响,强,负向中介,正向直接效应,弱中介,0.5765,否,0.4235,0.5765,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-2.6%。
431,疾病_前列腺增生 → 检验_钙 → 检验_嗜碱性粒细胞比率,-0.0125,-0.0367,0.0076,0.0118,-0.0166,-0.1302,0.0978,0.061,-0.0291,-0.1392,0.0834,0.06,-0.3858,-38.6,直接影响,强,负向中介,负向直接效应,部分中介,0.872,否,0.128,0.872,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-38.6%。
432,疾病_颈总动脉斑块 → 疾病_心律失常 → 疾病_慢性支气管炎,0.0429,0.0053,0.0809,0.02,-0.0789,-0.1925,0.0324,0.0617,-0.036,-0.1458,0.0665,0.059,-0.4815,-48.2,直接影响,强,正向中介,负向直接效应,部分中介,0.9885,是,0.9885,0.0115,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-48.2%。
433,疾病_颈总动脉斑块 → 疾病_肢体动脉硬化 → 药物_艾司唑仑片,0.1178,0.0578,0.1721,0.0302,-0.0658,-0.19,0.0426,0.0634,0.052,-0.045,0.175,0.0579,0.4484,44.8,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为44.8%。
434,疾病_颈总动脉斑块 → 疾病_老年性白内障 → 疾病_白内障,0.1204,0.0695,0.1763,0.0288,0.0399,-0.0815,0.1422,0.0584,0.1603,0.0481,0.2568,0.0555,0.8892,88.9,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为88.9%。
435,疾病_颈总动脉斑块 → 疾病_老年性白内障 → 检验_大型血小板比率,0.1249,0.0738,0.1768,0.0281,0.1324,0.023,0.2438,0.0592,0.2573,0.1487,0.3633,0.0577,0.5097,51.0,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为51.0%。
436,药物_叶酸片 → 药物_甲钴胺分散片 → 药物_卡维地洛片,0.068,0.0254,0.1047,0.0212,0.3845,0.2747,0.4855,0.0559,0.4525,0.3503,0.5455,0.0534,0.152,15.2,直接影响,强,正向中介,正向直接效应,弱中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为15.2%。
437,药物_叶酸片 → 药物_琥珀酸亚铁片 → 疾病_糖尿病性周围血管病,0.1177,0.057,0.1731,0.0306,0.002,-0.1193,0.1172,0.0628,0.1197,0.0121,0.2273,0.0571,1.4205,142.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为142.0%。
438,疾病_老年性白内障 → 检验_大型血小板比率 → 检验_血小板分布宽度,0.1961,0.1325,0.2563,0.0336,-0.0086,-0.1119,0.0932,0.0549,0.1875,0.0825,0.2923,0.0565,1.1573,115.7,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为115.7%。
439,疾病_老年性白内障 → 检验_大型血小板比率 → 疾病_医疗机构新收治患者及陪护人员,0.0675,0.0182,0.115,0.0257,0.0236,-0.0999,0.1308,0.0619,0.0912,-0.009,0.2011,0.0572,0.6266,62.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.998,是,0.998,0.002,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为62.7%。
440,药物_盐酸曲美他嗪片 → 药物_硫酸氢氯吡格雷片 → 药物_单硝酸异山梨酯片,0.165,0.0944,0.2361,0.0379,0.0983,-0.0119,0.22,0.0626,0.2633,0.1608,0.3621,0.0546,0.6564,65.6,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为65.6%。
441,药物_盐酸曲美他嗪片 → 药物_硫酸氢氯吡格雷片 → 疾病_陈旧性脑梗死,0.2186,0.1528,0.2827,0.0351,0.2556,0.1486,0.3536,0.0549,0.4742,0.3782,0.5643,0.0501,0.4647,46.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为46.5%。
442,药物_盐酸曲美他嗪片 → 疾病_低蛋白血症 → 检验_白球比,0.1847,0.1241,0.2468,0.033,0.0923,-0.0011,0.1926,0.0516,0.277,0.1753,0.3771,0.0536,0.6854,68.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为68.5%。
443,药物_盐酸曲美他嗪片 → 疾病_低蛋白血症 → 疾病_泌尿系感染,0.1188,0.0713,0.171,0.0268,0.1584,0.0481,0.267,0.0577,0.2773,0.1692,0.3821,0.0566,0.4451,44.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为44.5%。
444,药物_盐酸曲美他嗪片 → 疾病_低蛋白血症 → 检验_C反应蛋白,0.1556,0.0963,0.209,0.0302,0.0189,-0.0931,0.1254,0.0579,0.1745,0.0599,0.2752,0.0572,1.054,105.4,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为105.4%。
445,药物_盐酸曲美他嗪片 → 药物_阿卡波糖片 → 疾病_非毒性单个甲状腺结节,0.1257,0.0727,0.1779,0.0284,-0.1693,-0.2729,-0.0465,0.0612,-0.0436,-0.1548,0.0715,0.0608,-3.9545,-395.5,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-395.5%。
446,药物_盐酸曲美他嗪片 → 药物_阿卡波糖片 → 药物_精蛋白生物合成人胰岛素注射液,0.056,0.0123,0.1,0.023,0.1455,0.0382,0.2633,0.0601,0.2014,0.0991,0.3179,0.0572,0.3086,30.9,直接影响,强,正向中介,正向直接效应,部分中介,0.995,是,0.995,0.005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为30.9%。
447,药物_盐酸曲美他嗪片 → 药物_阿卡波糖片 → 检验_谷草转氨酶,0.0555,0.0131,0.0987,0.0233,0.0788,-0.0326,0.196,0.0625,0.1343,0.0239,0.2446,0.0584,0.575,57.5,直接影响,强,正向中介,正向直接效应,部分中介,0.992,是,0.992,0.008,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为57.5%。
448,药物_盐酸曲美他嗪片 → 药物_阿卡波糖片 → 疾病_糖尿病性周围神经病,0.1304,0.0786,0.1812,0.0279,0.042,-0.0733,0.1462,0.0586,0.1724,0.0613,0.2764,0.0578,-0.2287,-22.9,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-22.9%。
449,药物_盐酸曲美他嗪片 → 药物_阿卡波糖片 → 疾病_泌尿系感染,0.0735,0.0316,0.1185,0.0236,0.2035,0.0917,0.3129,0.0596,0.277,0.1709,0.3833,0.057,0.2765,27.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为27.6%。
450,药物_盐酸曲美他嗪片 → 疾病_陈旧性脑梗死 → 药物_硫酸氢氯吡格雷片,0.1867,0.1294,0.2448,0.0317,0.3337,0.238,0.4333,0.0514,0.5203,0.431,0.6166,0.0494,0.3606,36.1,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为36.1%。
451,药物_盐酸曲美他嗪片 → 疾病_陈旧性脑梗死 → 疾病_重度骨质疏松,0.1543,0.0899,0.2193,0.0348,-0.0457,-0.1722,0.0673,0.0647,0.1085,-0.001,0.2159,0.0579,6.4089,640.9,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为640.9%。
452,药物_阿卡波糖片 → 检验_谷草转氨酶 → 疾病_腰椎间盘突出,-0.0327,-0.0596,-0.0078,0.0146,0.1252,0.0112,0.2312,0.0599,0.0925,-0.0269,0.1995,0.0604,-0.8894,-88.9,直接影响,强,负向中介,正向直接效应,完全中介,0.9995,是,0.0005,0.9995,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-88.9%。
453,药物_阿卡波糖片 → 疾病_糖尿病性周围神经病 → 疾病_糖尿病性周围血管病,0.1844,0.1201,0.2431,0.0331,0.0471,-0.0499,0.1551,0.0544,0.2314,0.124,0.3331,0.0557,0.8407,84.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为84.1%。
454,药物_阿卡波糖片 → 疾病_糖尿病性周围神经病 → 疾病_糖尿病性视网膜病变,0.1229,0.0757,0.1792,0.0277,0.121,0.0177,0.2429,0.0598,0.2439,0.1306,0.3427,0.0568,0.5328,53.3,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为53.3%。
455,药物_阿卡波糖片 → 疾病_糖尿病性周围神经病 → 疾病_高尿酸血症,0.1495,0.0995,0.2129,0.0307,-0.0971,-0.2059,0.0109,0.0586,0.0524,-0.0585,0.1523,0.0572,4.7251,472.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为472.5%。
456,药物_阿卡波糖片 → 疾病_糖尿病性周围神经病 → 药物_甲钴胺片,0.0977,0.0473,0.1472,0.0266,0.029,-0.0845,0.1471,0.0611,0.1267,0.0156,0.2303,0.0569,1.067,106.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为106.7%。
457,疾病_腔隙性脑梗死 → 疾病_高尿酸血症 → 药物_碳酸氢钠片,-0.0095,-0.0481,0.0322,0.0216,0.0457,-0.0659,0.137,0.054,0.0362,-0.0704,0.1422,0.0575,-0.0377,-3.8,直接影响,强,负向中介,正向直接效应,弱中介,0.6725,否,0.3275,0.6725,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-3.8%。
458,疾病_腔隙性脑梗死 → 疾病_高尿酸血症 → 药物_硝苯地平控释片,-0.0089,-0.0461,0.0305,0.0202,-0.0171,-0.1233,0.0835,0.0546,-0.026,-0.1279,0.0844,0.0576,-0.0281,-2.8,直接影响,强,负向中介,负向直接效应,弱中介,0.6675,否,0.3325,0.6675,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-2.8%。
459,疾病_陈旧性脑梗死 → 药物_硫酸氢氯吡格雷片 → 药物_单硝酸异山梨酯片,0.1808,0.1089,0.2615,0.0405,0.0646,-0.0604,0.1902,0.0667,0.2454,0.14,0.345,0.057,0.7823,78.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为78.2%。
460,疾病_陈旧性脑梗死 → 药物_硫酸氢氯吡格雷片 → 药物_盐酸曲美他嗪片,0.2063,0.1355,0.2778,0.037,0.2695,0.1491,0.363,0.0566,0.4758,0.3795,0.5635,0.0497,0.4371,43.7,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为43.7%。
461,疾病_陈旧性脑梗死 → 疾病_重度骨质疏松 → 药物_骨化三醇胶丸,0.1692,0.1055,0.2293,0.0338,0.0563,-0.0439,0.1475,0.0511,0.2255,0.1233,0.3362,0.057,0.7923,79.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为79.2%。
462,疾病_陈旧性脑梗死 → 疾病_重度骨质疏松 → 药物_碳酸钙片,0.1236,0.0741,0.1751,0.0273,-0.0669,-0.1831,0.0378,0.0585,0.0567,-0.0448,0.169,0.0582,-2.5264,-252.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-252.6%。
463,疾病_糖尿病性周围血管病 → 疾病_血糖控制不佳 → 药物_精蛋白生物合成人胰岛素注射液,0.0164,-0.0526,0.0847,0.0362,0.1454,0.0268,0.2884,0.0696,0.1618,0.0477,0.2714,0.0593,0.1396,14.0,直接影响,强,正向中介,正向直接效应,弱中介,0.679,否,0.679,0.321,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为14.0%。
464,药物_硝苯地平控释片 → 药物_厄贝沙坦氢氯噻嗪片 → 疾病_低钾血症,0.0803,0.0383,0.1259,0.0235,-0.0422,-0.144,0.0792,0.0585,0.0381,-0.0619,0.1546,0.0564,-7.7352,-773.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-773.5%。
465,疾病_医疗机构新收治患者及陪护人员 → 疾病_慢性胃炎 → 疾病_结肠息肉,0.0711,0.0334,0.1088,0.0206,-0.1076,-0.2165,-0.0019,0.0575,-0.0365,-0.1445,0.0678,0.0573,17.1303,1713.0,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为1713.0%。
466,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 药物_阿司匹林肠溶片,0.0695,0.0315,0.1088,0.0212,0.021,-0.087,0.119,0.0552,0.0905,-0.012,0.1914,0.0559,0.6538,65.4,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为65.4%。
467,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 药物_富马酸比索洛尔片,0.0586,0.0248,0.0997,0.0204,-0.0355,-0.1452,0.0753,0.0595,0.0232,-0.0799,0.1418,0.0592,1.1407,114.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为114.1%。
468,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 药物_硝苯地平控释片,0.0593,0.0245,0.0967,0.0201,-0.1163,-0.226,-0.0117,0.058,-0.057,-0.1622,0.0428,0.0568,9.3312,933.1,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为933.1%。
469,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_肝功能异常,0.0373,0.01,0.0715,0.0168,-0.0248,-0.1494,0.0804,0.0599,0.0126,-0.1026,0.1203,0.0588,-2.1792,-217.9,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.997,是,0.997,0.003,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-217.9%。
470,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 药物_厄贝沙坦氢氯噻嗪片,0.0471,0.015,0.0802,0.0177,-0.1141,-0.2243,-0.0019,0.059,-0.067,-0.1714,0.0481,0.0583,-0.2815,-28.2,直接影响,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-28.2%。
471,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_糖尿病,0.0671,0.0318,0.1054,0.0201,-0.0381,-0.1614,0.0611,0.0582,0.0289,-0.0739,0.1424,0.0577,2.5928,259.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为259.3%。
472,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_反流性食管炎,0.0134,-0.0143,0.0401,0.0141,-0.1092,-0.2222,0.0077,0.0608,-0.0958,-0.2059,0.0131,0.0593,-0.2231,-22.3,直接影响,强,正向中介,负向直接效应,部分中介,0.849,否,0.849,0.151,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-22.3%。
473,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_动脉硬化,0.0331,0.0044,0.0624,0.0159,0.0727,-0.0432,0.18,0.0586,0.1058,-0.0018,0.2102,0.0566,-1.3598,-136.0,直接影响,强,正向中介,正向直接效应,完全中介,0.9925,是,0.9925,0.0075,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-136.0%。
474,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_脂肪肝,0.0525,0.0204,0.0886,0.0187,-0.0282,-0.1367,0.0912,0.0604,0.0242,-0.0877,0.1396,0.0603,0.4934,49.3,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为49.3%。
475,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_混合痔,-0.0619,-0.0965,-0.0277,0.0191,-0.0385,-0.1456,0.0786,0.0589,-0.1004,-0.2139,0.0066,0.0588,0.858,85.8,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为85.8%。
476,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 检验_嗜酸性粒细胞数量,-0.0106,-0.0362,0.0197,0.0148,0.0432,-0.0637,0.1634,0.061,0.0326,-0.0717,0.1464,0.0592,-0.7763,-77.6,直接影响,强,负向中介,正向直接效应,部分中介,0.7675,否,0.2325,0.7675,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-77.6%。
477,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_非毒性多个甲状腺结节,0.0215,-0.0062,0.0522,0.0154,0.023,-0.0942,0.132,0.0601,0.0444,-0.0691,0.1455,0.0575,-0.4992,-49.9,直接影响,强,正向中介,正向直接效应,部分中介,0.939,否,0.939,0.061,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-49.9%。
478,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 检验_红细胞压积,-0.0022,-0.0318,0.0224,0.0143,-0.1593,-0.2651,-0.0371,0.0596,-0.1615,-0.2684,-0.0485,0.0576,0.0131,1.3,直接影响,强,负向中介,负向直接效应,弱中介,0.566,否,0.434,0.566,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为1.3%。
479,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 药物_贞芪扶正,-0.0144,-0.0409,0.0125,0.0142,-0.0401,-0.1502,0.0801,0.0615,-0.0545,-0.1658,0.0528,0.0599,0.0858,8.6,直接影响,强,负向中介,负向直接效应,弱中介,0.857,否,0.143,0.857,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为8.6%。
480,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 检验_谷丙转氨酶,0.0093,-0.0188,0.0377,0.0151,0.0319,-0.0803,0.148,0.0612,0.0412,-0.0625,0.1568,0.0588,-0.1793,-17.9,直接影响,强,正向中介,正向直接效应,弱中介,0.7345,否,0.7345,0.2655,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-17.9%。
481,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 药物_盐酸二甲双胍片,0.0435,0.0116,0.0759,0.0176,0.0299,-0.0921,0.1372,0.0603,0.0735,-0.0367,0.1848,0.0584,0.3477,34.8,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为34.8%。
482,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_前列腺增生,0.0307,0.002,0.0614,0.0163,-0.0278,-0.1439,0.0861,0.0614,0.0029,-0.1129,0.1031,0.0591,3.2558,325.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9865,是,0.9865,0.0135,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为325.6%。
483,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_陈旧性脑梗死,0.0494,0.0176,0.0845,0.0182,0.0778,-0.038,0.1866,0.0605,0.1271,0.0193,0.2397,0.0593,0.5482,54.8,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为54.8%。
484,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 检验_血小板比容,-0.0476,-0.0806,-0.0156,0.0178,0.0006,-0.1111,0.111,0.059,-0.0469,-0.1515,0.0636,0.0579,1.7402,174.0,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为174.0%。
485,药物_苯磺酸氨氯地平片 → 疾病_高血压 → 疾病_肝囊肿,0.0151,-0.0133,0.0455,0.0153,0.0792,-0.0246,0.1973,0.0604,0.0943,-0.0182,0.1953,0.0589,0.1233,12.3,直接影响,强,正向中介,正向直接效应,弱中介,0.8655,否,0.8655,0.1345,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为12.3%。
486,检验_红细胞分布宽度SD → 检验_红细胞 → 检验_血红蛋白,0.2501,0.1822,0.3177,0.0368,0.1009,0.0141,0.1899,0.0481,0.351,0.2533,0.4479,0.0535,0.7223,72.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为72.2%。
487,检验_红细胞分布宽度SD → 检验_红细胞 → 疾病_贫血,0.1002,0.0468,0.156,0.0288,-0.0566,-0.1699,0.0638,0.0635,0.0436,-0.0577,0.1562,0.058,0.8331,83.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为83.3%。
488,检验_红细胞分布宽度SD → 检验_红细胞 → 检验_白蛋白,0.1279,0.0702,0.1827,0.0306,-0.0109,-0.1177,0.1029,0.0605,0.117,0.0033,0.2151,0.0569,1.9032,190.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为190.3%。
489,检验_红细胞分布宽度SD → 检验_红细胞 → 疾病_白内障,0.0375,-0.0102,0.0903,0.027,-0.1042,-0.2291,0.0203,0.0661,-0.0667,-0.1838,0.0396,0.0599,-1.5069,-150.7,直接影响,强,正向中介,负向直接效应,完全中介,0.9245,否,0.9245,0.0755,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-150.7%。
490,检验_红细胞分布宽度SD → 检验_红细胞平均体积 → 检验_平均血红蛋白含量,0.096,0.0445,0.1539,0.03,-0.0532,-0.1551,0.0467,0.0531,0.0428,-0.0639,0.1471,0.0571,3.8272,382.7,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为382.7%。
491,检验_红细胞 → 检验_血红蛋白 → 检验_红细胞分布宽度CV,0.2291,0.1415,0.3232,0.0485,0.1511,0.0336,0.2766,0.0657,0.3803,0.282,0.4789,0.0519,0.6117,61.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为61.2%。
492,检验_红细胞 → 检验_血红蛋白 → 检验_红细胞压积,0.3287,0.2487,0.409,0.0438,0.1739,0.0602,0.2861,0.0598,0.5026,0.4092,0.5962,0.0504,0.659,65.9,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为65.9%。
493,检验_红细胞 → 检验_血红蛋白 → 疾病_低蛋白血症,0.1349,0.0439,0.2267,0.0485,0.1595,0.0257,0.308,0.0746,0.2944,0.1931,0.397,0.0549,0.4785,47.8,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为47.8%。
494,检验_红细胞 → 检验_血红蛋白 → 检验_胆碱酯酶,0.2657,0.1708,0.3699,0.0521,-0.0948,-0.235,0.0297,0.0709,0.1709,0.0684,0.2749,0.0552,1.744,174.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为174.4%。
495,检验_红细胞 → 疾病_贫血 → 药物_琥珀酸亚铁片,0.0536,0.0199,0.09,0.0191,0.0631,-0.0458,0.1728,0.0585,0.1167,0.0127,0.2329,0.0588,2.2481,224.8,直接影响,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为224.8%。
496,检验_红细胞 → 检验_白蛋白 → 检验_总蛋白,0.1236,0.073,0.1729,0.0277,0.1026,0.0025,0.2061,0.055,0.2262,0.1205,0.3289,0.0557,0.5766,57.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为57.7%。
497,检验_红细胞压积 → 检验_红细胞分布宽度CV → 检验_钾,0.1162,0.0657,0.1695,0.0283,-0.0291,-0.1373,0.0792,0.0586,0.0871,-0.0147,0.1939,0.0565,2.3199,232.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为232.0%。
498,检验_红细胞压积 → 检验_红细胞分布宽度CV → 检验_红细胞分布宽度SD,0.2478,0.1725,0.3207,0.0402,0.0114,-0.0754,0.1035,0.0485,0.2591,0.157,0.3633,0.0568,0.9917,99.2,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为99.2%。
499,检验_红细胞压积 → 检验_红细胞分布宽度CV → 疾病_胆囊结石,0.0899,0.0409,0.1394,0.0264,-0.0715,-0.1923,0.0408,0.0625,0.0184,-0.0956,0.1266,0.0597,10.4972,1049.7,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为1049.7%。
500,检验_红细胞压积 → 检验_红细胞分布宽度CV → 检验_血小板,0.0389,-0.0071,0.0806,0.0234,0.1542,0.0405,0.2671,0.062,0.1931,0.0793,0.2936,0.0581,0.3891,38.9,直接影响,强,正向中介,正向直接效应,部分中介,0.9545,是,0.9545,0.0455,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.9%。
501,检验_红细胞压积 → 检验_红细胞分布宽度CV → 检验_磷,0.0599,0.0174,0.108,0.0246,0.0365,-0.0838,0.1471,0.0624,0.0964,-0.0176,0.1992,0.0586,0.7884,78.8,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.9945,是,0.9945,0.0055,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为78.8%。
502,检验_红细胞压积 → 检验_红细胞分布宽度CV → 检验_镁,0.0924,0.0433,0.1455,0.0269,0.0459,-0.0679,0.1594,0.0616,0.1383,0.0244,0.239,0.0581,0.8662,86.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为86.6%。
503,检验_红细胞压积 → 检验_红细胞分布宽度CV → 检验_谷草/谷丙,0.0687,0.0236,0.1177,0.0252,0.174,0.0634,0.2858,0.0599,0.2428,0.1365,0.3443,0.0559,0.303,30.3,直接影响,强,正向中介,正向直接效应,部分中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为30.3%。
504,检验_红细胞压积 → 检验_红细胞 → 检验_血红蛋白,0.23,0.1743,0.2949,0.032,0.386,0.2969,0.469,0.0461,0.616,0.5272,0.6979,0.0451,0.3742,37.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为37.4%。
505,检验_红细胞压积 → 检验_红细胞 → 疾病_贫血,0.0835,0.0197,0.148,0.0344,0.1135,-0.0019,0.2363,0.0645,0.197,0.0828,0.2957,0.0562,0.5037,50.4,直接影响,强,正向中介,正向直接效应,部分中介,0.994,是,0.994,0.006,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为50.4%。
506,检验_红细胞压积 → 检验_红细胞 → 检验_白蛋白,0.1114,0.0467,0.1773,0.0344,0.1754,0.0467,0.291,0.0654,0.2868,0.1879,0.3959,0.0566,0.4049,40.5,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为40.5%。
507,检验_红细胞压积 → 检验_红细胞 → 疾病_白内障,0.0394,-0.0208,0.107,0.0337,-0.0556,-0.175,0.0753,0.0666,-0.0163,-0.1214,0.09,0.0568,-1.3544,-135.4,直接影响,强,正向中介,负向直接效应,完全中介,0.8855,否,0.8855,0.1145,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-135.4%。
508,检验_红细胞压积 → 检验_直接胆红素 → 检验_总胆汁酸,0.0209,-0.0115,0.0546,0.0177,0.0066,-0.0959,0.1223,0.0577,0.0275,-0.08,0.1436,0.0599,0.1649,16.5,间接影响（中介效应）,强,正向中介,正向直接效应,弱中介,0.8925,否,0.8925,0.1075,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为16.5%。
509,检验_红细胞压积 → 检验_直接胆红素 → 检验_碱性磷酸酶,0.0224,-0.0098,0.0562,0.0184,0.1748,0.0787,0.2853,0.0551,0.1972,0.0916,0.3059,0.0581,0.1157,11.6,直接影响,强,正向中介,正向直接效应,弱中介,0.897,否,0.897,0.103,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为11.6%。
510,检验_红细胞压积 → 检验_直接胆红素 → 药物_盐酸羟考酮缓释片,0.0243,-0.0106,0.0619,0.0198,0.1187,0.0215,0.2302,0.0551,0.1431,0.0393,0.2508,0.0583,0.1595,15.9,直接影响,强,正向中介,正向直接效应,弱中介,0.899,否,0.899,0.101,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为15.9%。
511,检验_红细胞压积 → 检验_直接胆红素 → 检验_总胆红素,0.0396,-0.0213,0.0952,0.0316,-0.0834,-0.1724,0.0094,0.0484,-0.0438,-0.1485,0.0709,0.0586,0.9239,92.4,直接影响,强,正向中介,负向直接效应,完全中介,0.906,否,0.906,0.094,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为92.4%。
512,检验_红细胞压积 → 检验_直接胆红素 → 疾病_泌尿系感染,-0.0085,-0.0248,0.005,0.0083,0.1185,0.0039,0.2271,0.0595,0.11,-0.0007,0.2214,0.06,0.0198,2.0,直接影响,强,负向中介,正向直接效应,弱中介,0.8895,否,0.1105,0.8895,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为2.0%。
513,检验_红细胞压积 → 药物_碳酸氢钠片 → 检验_磷,0.0288,0.0031,0.0535,0.0142,0.0685,-0.0494,0.1725,0.0582,0.0973,-0.0167,0.2061,0.0582,-0.0039,-0.4,直接影响,强,正向中介,正向直接效应,弱中介,0.9945,是,0.9945,0.0055,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为-0.4%。
514,疾病_脑梗死 → 药物_肝素钠注射液 → 药物_氯化钠注射液,0.2833,0.2107,0.3614,0.0399,-0.0044,-0.1135,0.1074,0.059,0.2789,0.1783,0.3822,0.055,1.0549,105.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为105.5%。
515,疾病_脑梗死 → 疾病_糖尿病性视网膜病变 → 疾病_白内障,0.008,-0.0238,0.0368,0.0162,-0.0373,-0.1454,0.0642,0.0564,-0.0293,-0.1378,0.0781,0.0584,0.2664,26.6,直接影响,强,正向中介,负向直接效应,部分中介,0.6875,否,0.6875,0.3125,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为26.6%。
516,疾病_脑梗死 → 疾病_糖尿病性视网膜病变 → 药物_厄贝沙坦片,0.007,-0.0173,0.0335,0.0136,0.0216,-0.0846,0.1415,0.0599,0.0286,-0.0877,0.141,0.0611,0.2847,28.5,直接影响,强,正向中介,正向直接效应,部分中介,0.7055,否,0.7055,0.2945,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为28.5%。
517,检验_胆碱酯酶 → 检验_前白蛋白 → 检验_镁,0.1656,0.1,0.2432,0.0378,0.0439,-0.0788,0.1603,0.0642,0.2095,0.098,0.3074,0.0568,0.8579,85.8,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为85.8%。
518,检验_胆碱酯酶 → 检验_前白蛋白 → 检验_总胆红素,0.168,0.1011,0.238,0.037,0.0743,-0.0562,0.1883,0.0644,0.2423,0.134,0.346,0.0571,0.7349,73.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为73.5%。
519,检验_平均血红蛋白含量 → 疾病_贫血 → 药物_琥珀酸亚铁片,0.0435,0.0129,0.075,0.0174,0.0424,-0.064,0.1527,0.0584,0.0859,-0.0212,0.1944,0.059,0.5451,54.5,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为54.5%。
520,检验_总胆汁酸 → 检验_转肽酶 → 疾病_恶性肿瘤维持性化学治疗,0.0868,0.0432,0.1299,0.0239,0.0232,-0.084,0.1286,0.0574,0.11,0.0065,0.2206,0.0576,1.2833,128.3,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为128.3%。
521,检验_总胆汁酸 → 检验_转肽酶 → 检验_碱性磷酸酶,0.129,0.0746,0.1814,0.0294,0.0875,-0.0104,0.1895,0.0537,0.2165,0.1138,0.3179,0.0565,0.6314,63.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为63.1%。
522,检验_总胆汁酸 → 检验_转肽酶 → 药物_骨化三醇胶丸,-0.0027,-0.0358,0.0334,0.0179,-0.0356,-0.1474,0.0813,0.0622,-0.0383,-0.1471,0.0719,0.0595,0.829,82.9,直接影响,强,负向中介,负向直接效应,完全中介,0.565,否,0.435,0.565,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为82.9%。
523,检验_总胆汁酸 → 检验_转肽酶 → 疾病_非毒性单个甲状腺结节,0.0392,0.0048,0.0777,0.0191,0.0271,-0.0945,0.138,0.0619,0.0663,-0.0484,0.1721,0.0593,1.1763,117.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,0.987,是,0.987,0.013,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为117.6%。
524,检验_白细胞 → 检验_中性粒细胞数量 → 检验_单核细胞数量,0.1316,0.0658,0.202,0.0365,0.1411,0.0171,0.2567,0.0638,0.2727,0.1737,0.3813,0.0558,0.5035,50.3,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为50.3%。
525,检验_白细胞 → 检验_中性粒细胞数量 → 检验_镁,0.0821,0.015,0.1474,0.0352,-0.0135,-0.1417,0.1114,0.0673,0.0687,-0.0376,0.184,0.0584,4.5317,453.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9935,是,0.9935,0.0065,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为453.2%。
526,检验_白细胞 → 检验_中性粒细胞数量 → 药物_复方鲜竹沥液,0.0499,-0.0186,0.1162,0.0361,-0.0315,-0.1645,0.0872,0.0668,0.0184,-0.0919,0.1165,0.0567,-1.6135,-161.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.923,否,0.923,0.077,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-161.3%。
527,检验_白细胞 → 检验_中性粒细胞数量 → 药物_苯磺酸氨氯地平片,-0.066,-0.1343,0.0009,0.0361,-0.0079,-0.1206,0.1296,0.0679,-0.0739,-0.1786,0.0366,0.0578,-6.9794,-697.9,间接影响（中介效应）,强,负向中介,负向直接效应,完全中介,0.971,是,0.029,0.971,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-697.9%。
528,检验_白细胞 → 药物_二羟丙茶碱注射液 → 药物_阿卡波糖片,-0.0255,-0.0626,0.0142,0.0202,0.0062,-0.1058,0.1071,0.0561,-0.0193,-0.1384,0.0864,0.0592,1.3551,135.5,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,0.9035,否,0.0965,0.9035,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为135.5%。
529,检验_白细胞 → 药物_二羟丙茶碱注射液 → 药物_富马酸比索洛尔片,-0.0137,-0.0374,0.0096,0.0125,0.0829,-0.0279,0.1914,0.0593,0.0692,-0.0408,0.1833,0.0605,-0.5099,-51.0,直接影响,强,负向中介,正向直接效应,部分中介,0.8875,否,0.1125,0.8875,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-51.0%。
530,检验_白细胞 → 药物_二羟丙茶碱注射液 → 药物_酒石酸美托洛尔片,-0.0212,-0.0568,0.0088,0.0175,-0.027,-0.1326,0.0716,0.0542,-0.0482,-0.1571,0.0584,0.0573,-0.2007,-20.1,直接影响,强,负向中介,负向直接效应,部分中介,0.9005,否,0.0995,0.9005,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-20.1%。
531,检验_白细胞 → 药物_二羟丙茶碱注射液 → 药物_维生素C注射液,-0.0197,-0.0496,0.0085,0.0159,0.0868,-0.034,0.1832,0.0577,0.0671,-0.0514,0.1694,0.0596,-5.0048,-500.5,直接影响,强,负向中介,正向直接效应,完全中介,0.9095,否,0.0905,0.9095,该路径的中介效应不显著。 中介效应强度为完全中介，中介比例为-500.5%。
532,疾病_胆囊结石 → 疾病_脂肪肝 → 检验_C反应蛋白,-0.0634,-0.1028,-0.0245,0.0215,-0.0452,-0.1534,0.0748,0.0613,-0.1086,-0.2162,0.0008,0.0584,0.4782,47.8,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,0.999,是,0.001,0.999,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为47.8%。
533,疾病_胆囊结石 → 疾病_脂肪肝 → 疾病_糖尿病性周围血管病,0.076,0.0327,0.1225,0.0239,0.1393,0.0299,0.251,0.0605,0.2153,0.1096,0.3275,0.0582,0.3863,38.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.6%。
534,疾病_胆囊结石 → 疾病_脂肪肝 → 疾病_肺恶性肿瘤,0.1037,0.0584,0.154,0.026,-0.1624,-0.2676,-0.0451,0.059,-0.0588,-0.1731,0.0407,0.0579,-40.4312,-4043.1,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-4043.1%。
535,疾病_胆囊结石 → 检验_钙 → 检验_嗜碱性粒细胞比率,0.002,-0.0068,0.013,0.0053,0.0649,-0.0429,0.178,0.0593,0.067,-0.0381,0.1855,0.0595,0.0117,1.2,直接影响,强,正向中介,正向直接效应,弱中介,0.6455,否,0.6455,0.3545,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为1.2%。
536,疾病_脂肪肝 → 疾病_胆囊结石 → 检验_钙,0.0023,-0.041,0.0379,0.0206,-0.1031,-0.2153,0.0114,0.0622,-0.1008,-0.214,-0.0009,0.0576,0.0373,3.7,直接影响,强,正向中介,负向直接效应,弱中介,0.5355,否,0.5355,0.4645,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为3.7%。
537,疾病_脂肪肝 → 疾病_胆囊结石 → 药物_盐酸二甲双胍片,0.0739,0.0311,0.1187,0.0234,0.2159,0.1087,0.3257,0.0585,0.2899,0.1852,0.391,0.056,0.2645,26.5,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为26.5%。
538,疾病_脂肪肝 → 疾病_胆囊结石 → 药物_甲钴胺片,0.0607,0.0174,0.105,0.0236,-0.0531,-0.1681,0.0628,0.0622,0.0077,-0.1038,0.1142,0.0592,-6.9965,-699.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9975,是,0.9975,0.0025,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-699.6%。
539,疾病_脂肪肝 → 检验_C反应蛋白 → 药物_复方鲜竹沥液,-0.0612,-0.1018,-0.029,0.0202,0.0604,-0.0555,0.168,0.059,-0.0007,-0.1196,0.1104,0.061,-2.1575,-215.8,间接影响（中介效应）,强,负向中介,正向直接效应,完全中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-215.8%。
540,疾病_脂肪肝 → 检验_C反应蛋白 → 疾病_低钾血症,-0.0742,-0.1167,-0.0338,0.0225,0.0419,-0.0539,0.1524,0.0554,-0.0323,-0.1374,0.0771,0.0576,0.4285,42.8,间接影响（中介效应）,强,负向中介,正向直接效应,部分中介,0.9995,是,0.0005,0.9995,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为42.8%。
541,疾病_脂肪肝 → 检验_C反应蛋白 → 检验_总蛋白,-0.0415,-0.0721,-0.0124,0.0165,-0.0947,-0.2005,0.0194,0.059,-0.1361,-0.2563,-0.0338,0.0596,0.4547,45.5,直接影响,强,负向中介,负向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为45.5%。
542,疾病_脂肪肝 → 疾病_糖尿病性周围血管病 → 疾病_血糖控制不佳,0.1454,0.0836,0.2043,0.033,0.0085,-0.0897,0.1051,0.053,0.1538,0.0517,0.2638,0.058,0.9273,92.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为92.7%。
543,疾病_脂肪肝 → 疾病_肺恶性肿瘤 → 疾病_前列腺增生,0.0287,0.0002,0.0617,0.0165,-0.0239,-0.138,0.0892,0.0603,0.0048,-0.1123,0.1041,0.0577,-0.2622,-26.2,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.972,是,0.972,0.028,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-26.2%。
544,疾病_脂肪肝 → 疾病_肺恶性肿瘤 → 疾病_恶性肿瘤维持性化学治疗,0.0783,0.0373,0.1195,0.0224,-0.047,-0.1564,0.0676,0.0588,0.0313,-0.0761,0.1394,0.0583,2.0026,200.3,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为200.3%。
545,疾病_脂肪肝 → 疾病_肺恶性肿瘤 → 检验_单核细胞数量,0.0165,-0.0139,0.0468,0.0163,-0.0994,-0.2102,0.0144,0.06,-0.083,-0.1852,0.0287,0.0575,-0.29,-29.0,直接影响,强,正向中介,负向直接效应,部分中介,0.8535,否,0.8535,0.1465,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-29.0%。
546,检验_钠 → 药物_重组人促红素注射液 → 疾病_尿毒症,0.3328,0.2452,0.4237,0.0481,0.0456,-0.0023,0.0961,0.0262,0.3785,0.2745,0.4726,0.0532,0.8815,88.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为88.1%。
547,检验_钠 → 药物_重组人促红素注射液 → 检验_磷,0.1308,0.0807,0.1911,0.0287,0.095,-0.0123,0.2071,0.0588,0.2258,0.1142,0.3325,0.0575,0.6211,62.1,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为62.1%。
548,检验_钠 → 药物_重组人促红素注射液 → 检验_谷丙转氨酶,0.1715,0.1085,0.2272,0.0322,-0.04,-0.151,0.062,0.0576,0.1315,0.0229,0.2411,0.0577,1.3351,133.5,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为133.5%。
549,检验_钠 → 检验_淋巴细胞比率 → 检验_中性粒细胞比率,0.2228,0.1431,0.2952,0.041,-0.1332,-0.2144,-0.0441,0.0454,0.0896,-0.0203,0.1901,0.057,5.9512,595.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为595.1%。
550,检验_钠 → 检验_淋巴细胞比率 → 检验_淋巴细胞数量,0.1303,0.0791,0.182,0.0281,0.0351,-0.0648,0.1403,0.0549,0.1654,0.0616,0.2756,0.0571,0.9682,96.8,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为96.8%。
551,检验_钠 → 检验_淋巴细胞比率 → 药物_维生素B6注射液,0.0507,0.0151,0.0948,0.0211,-0.0349,-0.1556,0.0729,0.062,0.0158,-0.0961,0.118,0.0585,1.0701,107.0,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9965,是,0.9965,0.0035,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为107.0%。
552,检验_钠 → 检验_葡萄糖 → 疾病_肝囊肿,-0.0528,-0.0864,-0.0201,0.0182,-0.0204,-0.1399,0.0896,0.0612,-0.0732,-0.1857,0.0427,0.0604,0.5949,59.5,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,1.0,是,0.0,1.0,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为59.5%。
553,检验_钠 → 检验_葡萄糖 → 疾病_糖尿病,0.1174,0.0664,0.1753,0.0296,-0.1751,-0.2709,-0.0704,0.0539,-0.0576,-0.1661,0.0476,0.0578,3.4166,341.7,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为341.7%。
554,检验_钠 → 检验_葡萄糖 → 药物_地西泮注射液,0.0383,0.0064,0.0692,0.017,-0.0344,-0.1494,0.0718,0.0603,0.0039,-0.1029,0.1137,0.0584,-0.5422,-54.2,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为-54.2%。
555,检验_钠 → 检验_葡萄糖 → 药物_碳酸钙片,-0.0073,-0.0344,0.0203,0.014,0.0689,-0.0426,0.1771,0.0593,0.0616,-0.0434,0.1686,0.0576,0.2604,26.0,直接影响,强,负向中介,正向直接效应,部分中介,0.717,否,0.283,0.717,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为26.0%。
556,检验_钠 → 检验_氯 → 药物_单硝酸异山梨酯缓释片,0.0962,0.0407,0.1599,0.0317,-0.0614,-0.1885,0.056,0.0642,0.0348,-0.0687,0.1472,0.0576,3.1388,313.9,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为313.9%。
557,检验_钠 → 检验_氯 → 药物_葡萄糖注射液,0.1319,0.0749,0.1936,0.0323,-0.0712,-0.1915,0.0454,0.0638,0.0607,-0.0491,0.1634,0.0578,1.5839,158.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为158.4%。
558,检验_嗜酸性粒细胞数量 → 检验_嗜酸性粒细胞比率 → 药物_硝苯地平控释片,-0.035,-0.1125,0.0375,0.0402,-0.0498,-0.1818,0.0879,0.0715,-0.0847,-0.1945,0.0211,0.0574,0.4434,44.3,直接影响,强,负向中介,负向直接效应,部分中介,0.809,否,0.191,0.809,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为44.3%。
559,检验_嗜酸性粒细胞数量 → 检验_嗜酸性粒细胞比率 → 疾病_医疗机构新收治患者及陪护人员,-0.0055,-0.0844,0.0685,0.0403,0.0703,-0.0693,0.1998,0.072,0.0648,-0.0466,0.1682,0.0581,-0.1234,-12.3,直接影响,强,负向中介,正向直接效应,弱中介,0.5675,否,0.4325,0.5675,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-12.3%。
560,检验_嗜酸性粒细胞数量 → 疾病_心功能 → 疾病_不稳定性心绞痛,0.0796,0.031,0.129,0.0267,-0.1207,-0.2326,-0.0319,0.054,-0.0412,-0.1581,0.0603,0.0588,-1.4939,-149.4,直接影响,强,正向中介,负向直接效应,完全中介,0.999,是,0.999,0.001,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-149.4%。
561,疾病_肢体动脉硬化 → 疾病_颈总动脉斑块 → 疾病_心律失常,0.1379,0.0763,0.1945,0.0319,-0.0069,-0.1315,0.1045,0.063,0.131,0.0181,0.2311,0.0575,1.4382,143.8,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为143.8%。
562,疾病_肢体动脉硬化 → 疾病_颈总动脉斑块 → 疾病_老年性白内障,0.1264,0.0733,0.1841,0.0299,0.2085,0.0906,0.3153,0.0596,0.3349,0.2343,0.4325,0.0536,0.3872,38.7,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为38.7%。
563,检验_球蛋白 → 检验_总蛋白 → 检验_钙,0.0868,0.0442,0.1347,0.0241,0.0137,-0.1067,0.1136,0.0592,0.1005,-0.0029,0.2093,0.0583,1.1499,115.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为115.0%。
564,检验_球蛋白 → 检验_总蛋白 → 检验_白蛋白,0.1448,0.0833,0.1973,0.031,-0.1535,-0.2575,-0.0496,0.0562,-0.0086,-0.1182,0.1006,0.0582,8.4224,842.2,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为842.2%。
565,检验_单核细胞比率 → 检验_白细胞 → 检验_中性粒细胞数量,0.0953,0.0385,0.1544,0.0318,-0.1637,-0.2468,-0.0603,0.0492,-0.0684,-0.1771,0.0339,0.0564,-3.8458,-384.6,直接影响,强,正向中介,负向直接效应,完全中介,0.9995,是,0.9995,0.0005,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-384.6%。
566,检验_单核细胞比率 → 检验_白细胞 → 药物_二羟丙茶碱注射液,-0.0109,-0.0339,0.0082,0.0112,-0.0565,-0.1675,0.0668,0.0626,-0.0675,-0.1773,0.0504,0.0611,0.1242,12.4,直接影响,强,负向中介,负向直接效应,弱中介,0.858,否,0.142,0.858,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为12.4%。
567,检验_白蛋白 → 检验_总蛋白 → 检验_钙,0.11,0.0524,0.1658,0.0302,0.0737,-0.0472,0.1957,0.0643,0.1837,0.0695,0.2915,0.0589,0.6999,70.0,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为70.0%。
568,检验_白蛋白 → 检验_总蛋白 → 检验_球蛋白,0.1629,0.1048,0.2292,0.0323,-0.1729,-0.292,-0.0592,0.0607,-0.0101,-0.1159,0.0973,0.0565,-5.3462,-534.6,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-534.6%。
569,药物_呋塞米片 → 药物_螺内酯片 → 药物_酒石酸美托洛尔片,0.2924,0.1658,0.4313,0.0709,0.0165,-0.1331,0.1824,0.0862,0.3089,0.2128,0.4101,0.0524,0.9754,97.5,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为97.5%。
570,药物_呋塞米片 → 药物_螺内酯片 → 药物_艾司唑仑片,0.0424,-0.1094,0.1691,0.0738,0.1521,-0.0194,0.3164,0.0914,0.1946,0.0914,0.301,0.0563,0.2405,24.0,直接影响,强,正向中介,正向直接效应,部分中介,0.7205,否,0.7205,0.2795,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为24.0%。
571,药物_单硝酸异山梨酯片 → 疾病_冠状动脉粥样硬化性心脏病 → 药物_盐酸曲美他嗪片,0.1443,0.0926,0.2017,0.0294,0.1175,0.0052,0.229,0.0602,0.2619,0.1506,0.3623,0.058,0.5782,57.8,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为57.8%。
572,药物_单硝酸异山梨酯片 → 疾病_冠状动脉粥样硬化性心脏病 → 疾病_不稳定性心绞痛,0.133,0.0815,0.1872,0.0285,0.193,0.0828,0.2935,0.0569,0.326,0.2276,0.4301,0.0552,0.4178,41.8,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为41.8%。
573,药物_单硝酸异山梨酯片 → 疾病_冠状动脉粥样硬化性心脏病 → 药物_阿托伐他汀钙片,0.0481,0.0029,0.0945,0.0245,0.2371,0.1189,0.349,0.0609,0.2852,0.1827,0.391,0.0559,0.1758,17.6,直接影响,强,正向中介,正向直接效应,弱中介,0.98,是,0.98,0.02,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为17.6%。
574,药物_单硝酸异山梨酯片 → 疾病_冠状动脉粥样硬化性心脏病 → 疾病_尿毒症,-0.041,-0.0895,0.0044,0.0248,-0.0024,-0.1178,0.1226,0.0632,-0.0435,-0.1565,0.0677,0.0587,0.5724,57.2,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,0.956,是,0.044,0.956,该路径存在显著的负向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为57.2%。
575,检验_肌酐 → 疾病_腔隙性脑梗死 → 药物_劳拉西泮片,-0.0355,-0.0666,-0.0083,0.0162,-0.0461,-0.1452,0.0716,0.0577,-0.0816,-0.1858,0.0337,0.059,0.5914,59.1,直接影响,强,负向中介,负向直接效应,部分中介,0.993,是,0.007,0.993,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为59.1%。
576,检验_肌酐 → 疾病_腔隙性脑梗死 → 疾病_高尿酸血症,0.0035,-0.0153,0.0213,0.0094,0.0047,-0.1097,0.1142,0.0601,0.0082,-0.1102,0.1151,0.06,-0.2293,-22.9,直接影响,强,正向中介,正向直接效应,部分中介,0.657,否,0.657,0.343,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为-22.9%。
577,疾病_贫血 → 药物_琥珀酸亚铁片 → 药物_叶酸片,0.1143,0.0646,0.168,0.0287,-0.04,-0.1407,0.0649,0.0558,0.0743,-0.0485,0.1723,0.0594,0.7517,75.2,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为75.2%。
578,疾病_贫血 → 药物_琥珀酸亚铁片 → 疾病_糖尿病性周围血管病,0.0655,0.0269,0.1021,0.0208,0.0403,-0.0635,0.1544,0.0594,0.1058,-0.0075,0.2083,0.0586,0.8306,83.1,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为83.1%。
579,药物_琥珀酸亚铁片 → 药物_叶酸片 → 药物_卡维地洛片,0.2103,0.1401,0.2724,0.0347,-0.0605,-0.1682,0.0437,0.056,0.1498,0.0393,0.2518,0.0549,1.7712,177.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为177.1%。
580,药物_琥珀酸亚铁片 → 药物_叶酸片 → 药物_甲钴胺分散片,0.1363,0.0819,0.1949,0.0306,0.0476,-0.0598,0.1607,0.0599,0.1839,0.0772,0.2805,0.0552,0.8498,85.0,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为85.0%。
581,药物_琥珀酸亚铁片 → 疾病_糖尿病性周围血管病 → 疾病_血糖控制不佳,0.1417,0.0818,0.1993,0.032,-0.0095,-0.1121,0.0868,0.052,0.1322,0.028,0.2411,0.0566,1.4106,141.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为141.1%。
582,检验_钙 → 检验_嗜碱性粒细胞比率 → 检验_嗜碱性粒细胞数量,-0.0325,-0.0784,0.0185,0.0262,-0.0284,-0.1323,0.069,0.0544,-0.0609,-0.17,0.0509,0.06,0.4982,49.8,间接影响（中介效应）,强,负向中介,负向直接效应,部分中介,0.895,否,0.105,0.895,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为49.8%。
583,疾病_肛乳头肥大 → 疾病_混合痔 → 药物_裸花紫珠分散片,0.3248,0.2536,0.4036,0.0406,0.1812,0.0831,0.2861,0.0536,0.506,0.4175,0.602,0.0506,0.6459,64.6,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为64.6%。
584,疾病_肛乳头肥大 → 疾病_混合痔 → 药物_头孢地尼分散片,0.2532,0.171,0.337,0.0446,-0.1047,-0.2251,0.0285,0.0685,0.1485,0.044,0.2526,0.0562,2.2585,225.8,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为225.8%。
585,检验_血小板 → 药物_维生素C注射液 → 药物_维生素B6注射液,0.1602,0.075,0.2452,0.0463,-0.0556,-0.1224,0.0081,0.0353,0.1047,-0.0048,0.208,0.057,1.8707,187.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为187.1%。
586,疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸 → 疾病_高尿酸血症,0.0515,0.0188,0.0859,0.0186,-0.168,-0.2734,-0.0619,0.0564,-0.1166,-0.2208,-0.0111,0.057,-0.9351,-93.5,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-93.5%。
587,疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸 → 疾病_重度骨质疏松,0.0059,-0.0171,0.0307,0.0125,-0.0416,-0.1539,0.0743,0.0618,-0.0357,-0.1477,0.0753,0.0602,0.0056,0.6,直接影响,强,正向中介,负向直接效应,弱中介,0.6925,否,0.6925,0.3075,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为0.6%。
588,疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸 → 检验_钾,0.0281,0.0021,0.0548,0.0144,0.1232,0.005,0.2284,0.0588,0.1513,0.0375,0.256,0.0574,0.2363,23.6,直接影响,强,正向中介,正向直接效应,部分中介,0.989,是,0.989,0.011,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为23.6%。
589,疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸 → 疾病_慢性胃炎,-0.0199,-0.0468,0.0003,0.0127,-0.0459,-0.1593,0.0647,0.0609,-0.0658,-0.1758,0.05,0.06,0.5133,51.3,直接影响,强,负向中介,负向直接效应,部分中介,0.968,是,0.032,0.968,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为51.3%。
590,疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸 → 药物_劳拉西泮片,0.0081,-0.0115,0.0357,0.0122,0.0252,-0.0841,0.1402,0.0589,0.0333,-0.0799,0.1379,0.058,0.2828,28.3,直接影响,强,正向中介,正向直接效应,部分中介,0.754,否,0.754,0.246,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为28.3%。
591,药物_碳酸钙片 → 药物_骨化三醇胶丸 → 疾病_类风湿性关节炎,0.1754,0.118,0.2395,0.0329,-0.0773,-0.1785,0.0405,0.0592,0.0981,-0.0143,0.2028,0.0585,2.866,286.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为286.6%。
592,药物_碳酸钙片 → 药物_骨化三醇胶丸 → 药物_酒石酸美托洛尔片,0.1355,0.0803,0.1935,0.0309,-0.0917,-0.2087,0.0262,0.062,0.0438,-0.0709,0.1462,0.0589,-1.8684,-186.8,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-186.8%。
593,药物_碳酸钙片 → 疾病_糖尿病性视网膜病变 → 疾病_白内障,0.0459,0.013,0.0796,0.0184,0.0241,-0.0937,0.1395,0.0608,0.07,-0.0424,0.1897,0.062,0.4716,47.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.999,是,0.999,0.001,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为47.2%。
594,药物_碳酸钙片 → 疾病_糖尿病性视网膜病变 → 药物_厄贝沙坦片,0.0406,0.012,0.0725,0.0171,-0.074,-0.1869,0.0409,0.0594,-0.0335,-0.1442,0.0855,0.0601,0.404,40.4,直接影响,强,正向中介,负向直接效应,部分中介,0.9985,是,0.9985,0.0015,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为40.4%。
595,检验_间接胆红素 → 检验_总胆红素 → 检验_直接胆红素,0.309,0.1732,0.4305,0.0675,0.2045,0.0423,0.3523,0.0816,0.5135,0.4196,0.5996,0.049,0.6068,60.7,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为60.7%。
596,检验_间接胆红素 → 检验_总胆红素 → 疾病_非毒性单个甲状腺结节,0.1173,-0.0298,0.2692,0.0807,0.0622,-0.1278,0.2424,0.0999,0.1795,0.0736,0.2909,0.0576,0.4515,45.2,间接影响（中介效应）,强,正向中介,正向直接效应,部分中介,0.922,否,0.922,0.078,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为45.2%。
597,药物_硫酸氢氯吡格雷片 → 药物_单硝酸异山梨酯片 → 疾病_冠状动脉粥样硬化性心脏病,0.111,0.0611,0.1605,0.0266,0.2461,0.1402,0.3499,0.0557,0.3571,0.2546,0.4533,0.0541,0.3164,31.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为31.6%。
598,药物_硫酸氢氯吡格雷片 → 药物_单硝酸异山梨酯片 → 疾病_类风湿性关节炎,0.1101,0.0606,0.1607,0.0273,0.0069,-0.1144,0.1138,0.0605,0.117,0.0091,0.2228,0.0572,0.9178,91.8,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为91.8%。
599,药物_硫酸氢氯吡格雷片 → 药物_盐酸曲美他嗪片 → 疾病_低蛋白血症,0.1868,0.1131,0.2574,0.0383,0.0181,-0.0998,0.1428,0.0646,0.2049,0.1006,0.3116,0.0574,1.0115,101.2,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为101.2%。
600,药物_硫酸氢氯吡格雷片 → 药物_盐酸曲美他嗪片 → 药物_阿卡波糖片,0.1719,0.0985,0.245,0.0386,0.0453,-0.0754,0.1711,0.0655,0.2173,0.1145,0.3215,0.0572,0.8568,85.7,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为85.7%。
601,药物_硫酸氢氯吡格雷片 → 药物_盐酸曲美他嗪片 → 疾病_陈旧性脑梗死,0.1348,0.0766,0.1944,0.0317,0.4165,0.3112,0.5192,0.0554,0.5513,0.4567,0.6356,0.0482,0.246,24.6,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为24.6%。
602,药物_硫酸氢氯吡格雷片 → 疾病_陈旧性脑梗死 → 疾病_重度骨质疏松,0.1753,0.1048,0.2531,0.0397,-0.0262,-0.1597,0.0922,0.0662,0.1491,0.046,0.2592,0.0572,1.6339,163.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为163.4%。
603,药物_酒石酸美托洛尔片 → 药物_富马酸比索洛尔片 → 药物_硝苯地平缓释片,-0.0243,-0.0564,0.0032,0.0162,0.1802,0.0777,0.285,0.0565,0.1559,0.0491,0.2651,0.0587,-0.1727,-17.3,直接影响,强,负向中介,正向直接效应,弱中介,0.945,否,0.055,0.945,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为-17.3%。
604,药物_酒石酸美托洛尔片 → 药物_富马酸比索洛尔片 → 疾病_心律失常,-0.0163,-0.0377,0.0047,0.0117,0.1036,0.001,0.2141,0.0581,0.0874,-0.0158,0.2045,0.0591,0.6401,64.0,直接影响,强,负向中介,正向直接效应,部分中介,0.947,否,0.053,0.947,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为64.0%。
605,药物_酒石酸美托洛尔片 → 药物_富马酸比索洛尔片 → 药物_甲钴胺片,-0.0054,-0.0203,0.0059,0.0072,-0.032,-0.1314,0.0853,0.0579,-0.0374,-0.1548,0.0632,0.0579,0.2007,20.1,直接影响,强,负向中介,负向直接效应,部分中介,0.825,否,0.175,0.825,该路径的中介效应不显著。 中介效应强度为部分中介，中介比例为20.1%。
606,疾病_心功能 → 疾病_不稳定性心绞痛 → 疾病_反流性食管炎,0.1184,0.0668,0.1715,0.0287,0.036,-0.0706,0.153,0.0601,0.1544,0.0534,0.2653,0.0562,0.9262,92.6,间接影响（中介效应）,强,正向中介,正向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为92.6%。
607,疾病_心功能 → 疾病_不稳定性心绞痛 → 药物_盐酸曲美他嗪片,0.2242,0.1565,0.2881,0.0352,-0.0449,-0.1424,0.059,0.0542,0.1793,0.0723,0.2781,0.0564,1.2963,129.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为129.6%。
608,检验_血小板比容 → 检验_血小板 → 药物_维生素C注射液,0.0804,0.0321,0.1267,0.0255,-0.1023,-0.2196,0.013,0.0625,-0.0219,-0.1419,0.0876,0.0599,11.1791,1117.9,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为1117.9%。
609,药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片 → 药物_单硝酸异山梨酯片,0.0843,0.0429,0.1257,0.0221,0.2016,0.096,0.3049,0.0559,0.2859,0.1839,0.39,0.0552,0.3045,30.4,直接影响,强,正向中介,正向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为30.4%。
610,药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片 → 药物_盐酸曲美他嗪片,0.1496,0.0901,0.2145,0.0336,-0.092,-0.1848,0.0064,0.0513,0.0577,-0.0497,0.1643,0.0575,2.7911,279.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为279.1%。
611,药物_阿托伐他汀钙片 → 药物_硫酸氢氯吡格雷片 → 疾病_陈旧性脑梗死,0.1559,0.0966,0.2182,0.0338,-0.0503,-0.1449,0.0409,0.05,0.1056,-0.0064,0.1977,0.0557,2.6765,267.6,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为267.6%。
612,药物_阿托伐他汀钙片 → 疾病_心律失常 → 疾病_慢性支气管炎,-0.0055,-0.0208,0.0063,0.0073,0.006,-0.1043,0.1185,0.0593,0.0005,-0.103,0.1206,0.0594,0.09,9.0,直接影响,强,负向中介,正向直接效应,弱中介,0.791,否,0.209,0.791,该路径的中介效应不显著。 中介效应强度为弱中介，中介比例为9.0%。
613,检验_磷 → 药物_碳酸钙片 → 药物_骨化三醇胶丸,0.0697,0.0261,0.1165,0.0251,-0.0015,-0.1027,0.1067,0.056,0.0682,-0.0427,0.1797,0.0592,-2.7516,-275.2,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9985,是,0.9985,0.0015,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为-275.2%。
614,检验_磷 → 药物_碳酸钙片 → 疾病_糖尿病性视网膜病变,0.0272,0.0027,0.0522,0.0138,0.0359,-0.0663,0.1622,0.0601,0.0631,-0.0574,0.1638,0.0599,-0.3308,-33.1,直接影响,强,正向中介,正向直接效应,部分中介,0.9965,是,0.9965,0.0035,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-33.1%。
615,药物_碳酸氢钠片 → 检验_磷 → 药物_碳酸钙片,0.0314,0.0055,0.0602,0.0153,0.0772,-0.0305,0.1851,0.0583,0.1086,0.0012,0.2121,0.0574,-0.5983,-59.8,直接影响,强,正向中介,正向直接效应,部分中介,0.995,是,0.995,0.005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为-59.8%。
616,疾病_肺恶性肿瘤 → 疾病_前列腺增生 → 检验_钙,0.0203,-0.001,0.044,0.0127,-0.0246,-0.1405,0.091,0.0607,-0.0043,-0.1185,0.1087,0.0603,0.1207,12.1,直接影响,强,正向中介,负向直接效应,弱中介,0.9765,是,0.9765,0.0235,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为弱中介，中介比例为12.1%。
617,疾病_肺恶性肿瘤 → 疾病_恶性肿瘤维持性化学治疗 → 检验_尿酸,0.0699,0.0282,0.1128,0.0228,-0.1324,-0.245,-0.0197,0.0607,-0.0625,-0.1704,0.0463,0.0582,-1.6333,-163.3,直接影响,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的负向直接效应，主要通过直接影响发挥作用。 中介效应强度为完全中介，中介比例为-163.3%。
618,疾病_低钾血症 → 疾病_心功能 → 疾病_不稳定性心绞痛,0.082,0.0381,0.1349,0.0261,-0.063,-0.158,0.0467,0.0547,0.019,-0.0791,0.1287,0.0578,4.9812,498.1,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为498.1%。
619,药物_富马酸比索洛尔片 → 疾病_心律失常 → 疾病_慢性支气管炎,0.0203,-0.001,0.0445,0.0125,-0.0027,-0.1054,0.1096,0.0586,0.0175,-0.0858,0.1288,0.0579,3.0445,304.4,间接影响（中介效应）,强,正向中介,负向直接效应,完全中介,0.9775,是,0.9775,0.0225,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为完全中介，中介比例为304.4%。
620,药物_厄贝沙坦氢氯噻嗪片 → 疾病_低钾血症 → 疾病_心功能,0.0446,0.013,0.0792,0.018,0.07,-0.0326,0.1883,0.0591,0.1145,0.0134,0.225,0.0572,0.6346,63.5,直接影响,强,正向中介,正向直接效应,部分中介,0.9995,是,0.9995,0.0005,该路径存在显著的正向直接效应，主要通过直接影响发挥作用。 中介效应强度为部分中介，中介比例为63.5%。
621,药物_厄贝沙坦氢氯噻嗪片 → 疾病_低钾血症 → 检验_钾,0.0784,0.0371,0.1208,0.0231,-0.0158,-0.1255,0.0934,0.0574,0.0626,-0.0406,0.1728,0.0571,0.4472,44.7,间接影响（中介效应）,强,正向中介,负向直接效应,部分中介,1.0,是,1.0,0.0,该路径存在显著的正向中介，主要通过间接影响发挥作用。 中介效应强度为部分中介，中介比例为44.7%。
